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A B S T R A C T
Background
The diagnosis and treatment of a brain or spinal cord tumour can have a huge impact on the lives of patients and their families with family
caregiving often resulting in considerable burden and distress. Meeting the support needs of family caregivers is critical to maintain
their emotional and physical health. Although support for caregivers is becoming more widely available, large-scale implementation is
hindered by a lack of high-quality evidence for its effectiveness in the neuro-oncology caregiver population.
Objectives
To assess the effectiveness of supportive interventions at improving the well-being of caregivers of people with a brain or spinal cord
tumour. To assess the effects of supportive interventions for caregivers in improving the physical and emotional well-being of people
with a brain or spinal cord tumour and to evaluate the health economic benefits of supportive interventions for caregivers.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL; 2018, Issue 7), MEDLINE via Ovid, and Embase via
Ovid. We also handsearched relevant published conference abstracts (previous five years), publications in the two main journals in the
field (previous year), searched for ongoing trials via ClinicalTrials.gov, and contacted research groups in the field. The initial search was
in March 2017 with an update in August 2018 (handsearches completed in January 2019).
Selection criteria
We included all randomised controlled trials (RCTs) where caregivers of neuro-oncology patients constituted more than 20% of the
sample and which evaluated changes in caregiver well-being following any supportive intervention.
Data collection and analysis
Two review authors independently selected studies and carried out risk of bias assessments. We aimed to extract data on the outcomes
of psychological distress, burden, mastery, quality of patient-caregiver relationship, quality of life, and physical functioning.
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Main results
In total, the search identified 2102 records, of which we reviewed 144 in full text. We included eight studies. Four interventions focused
on patient-caregiver dyads and four were aimed specifically at the caregiver. Heterogeneity of populations and methodologies precluded
meta-analysis. Risk of bias varied, and all studies included only small numbers of neuro-oncology caregivers (13 to 56 participants).
There was some evidence for positive effects of caregiver support on psychological distress, mastery, and quality of life (low to very low
certainty of evidence). No studies reported significant effects on caregiver burden or quality of patient-caregiver relationship (low to
very low certainty of evidence). None of the studies assessed caregiver physical functioning. For secondary outcomes (patient emotional
or physical well-being; health economic effects), we found very little to no evidence for the effectiveness of caregiver support. We
identified five ongoing trials.
Authors’ conclusions
The eight small-scale studies included employed different methodologies across different populations, with low certainty of evidence
overall. It is not currently possible to draw reliable conclusions regarding the effectiveness of supportive interventions aimed at improving
neuro-oncology caregiver well-being. More high-quality research is needed on support for family caregivers of people diagnosed, and
living, with a brain or spinal cord tumour.
P L A I N L A N G U A G E S U M M A R Y
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The issue
Family caregivers (e.g. spouses, family members or close friends) often provide physical and emotional support to peoples with a brain
or spinal tumour (cancer). However, family caregiving is linked to considerable burden and distress. Therefore, it is important to meet
the support needs of family caregivers so their emotional and physical health is maintained. This is expected to help the caregiver, the
patient, and the family unit.
The aim of the review
To assess the effectiveness of supportive interventions at improving the well-being of caregivers of people with a brain or spinal cord
tumour. To assess the effects of supportive interventions for caregivers in improving the physical and emotional well-being of patients
with a brain or spinal cord tumour and to evaluate the health economic benefits of supportive interventions for caregivers.
Study characteristics
We included eight clinical studies. Four studies reported on interventions for patient-caregiver relationship and four studies were aimed
specifically at improving caregiver well-being. We found five ongoing studies.
What were the main findings?
The interventions tested were diverse in nature (e.g. cognitive behavioural therapy (talking therapy); psychoeducation (providing
education and information to people seeking or receivingmental health services); coping skills training; self-management; social network
intervention); and delivery (e.g. face-to-face; web-based), and all studies were relatively small (included between 13 and 56 neuro-
oncology caregivers). We found some evidence for positive effects of caregiver support on psychological distress, feelings of mastery
(i.e. the feeling of being in control of the caregiving situation), and quality of life.
Reliability of the evidence
None of the studies reported effects on caregiver burden or quality of patient-caregiver relationship. None of the studies measured
caregiver physical well-being. Overall, the certainty of the evidence was low to very low, which means the true effect of caregiver support
may be substantially different.
Conclusions
Our findings suggest it is not currently possible to draw definitive conclusions about the effectiveness of supportive interventions
to improve neuro-oncology caregiver well-being. More high-quality research is needed on support for family caregivers of patients
diagnosed, and living, with a brain or spinal cord tumour.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Interventions to help support caregivers of people with a brain or spinal cord tumour
Patient or population: caregiver well-being
Setting: any
Intervention: support ive intervent ions
Comparison: any control condit ion
Outcomes Impact of participants
(studies)
Certainty of the evidence
(GRADE)
Caregiver psychological distress
assessed with: DASS-21; Fear of Recur-
rence Quest ionnaire - Family Member; CES-
D; POMS; STAI; HADS
Follow-up: range 1 days to 8 months
4 studies found improvements af ter the
intervent ion (early palliat ive care; inter-
act ive-educat ional programme; electronic
social network intervent ion; self -manage-
ment programme); 1 found no signif icant
ef fects (e-mental health); 1 only reported
descript ives (cognit ive rehabilitat ion and
problem-solving)
(6 RCTs) ⊕⊕©©
Lowa,b,c,d,e
Caregiver burden
assessed with: MBCB Scale; Zarit Care-
giver Burden Scale
Follow-up: range 6 weeks to 3 months
2 studies found no stat ist ically signif icant
dif f erences in burden scales between the
intervent ion and control groups (early vs
delayed palliat ive care; electronic social
network intervent ion)
(2 RCTs) ⊕⊕©©
Lowe
Caregiver mastery
assessed with: Caregiver Mastery Scale;
General Self -Ef f icacy Scale;Utrecht Coping
List
Follow-up: range 6 months to 8 months
1 study found improvements in mastery af -
ter the intervent ion (psychoeducat ion and
cognit ive behavioural therapy) compared
to care-as-usual, corrected for changes
in pat ient funct ioning. 1 study found no
improvements in self -ef f icacy or coping
strategies (self -management programme)
(2 RCTs) ⊕©©©
Very lowd,e,f,g
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Quality of patient-caregiver relationship
assessed with: McMaster Family Assess-
ment Device
1 study found no stat ist ically signif icant
dif f erences in family funct ioning between
the intervent ion and control groups (e-
mental health vs wait ing list)
(1 RCT) ⊕©©©
Very lowe,h
Caregiver quality of life
assessed with: SF-36; QoL - Family Care-
giver Tool; CQOLC; LASA
Follow-up: range 30 days to 8 months
2 studies found improvements in QoL over
t ime in the intervent ion group (psychoso-
cial intervent ion; self -management pro-
gramme) compared to the control group; 1
study found stable QoL in the intervent ion
group vs decline in the control group (no
longer stat ist ically signif icant af ter con-
trolling for pat ient funct ioning); 2 stud-
ies found no stat ist ically signif icant im-
provements af ter the intervent ion (e-men-
tal health; early palliat ive care); 1 only re-
ported descript ives (cognit ive rehabilita-
t ion and problem-solving)
(6 RCTs) ⊕©©©
Very lowa,b,c,e,g,i
Caregiver physical functioning - not mea-
sured
None of the included studies assessed
caregiver physical funct ioning
- -
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CQOLC: Caregiver QoL Index - Cancer; CES-D: Center for Epidemiological Studies Depression Scale; CI: conf idence interval; DASS-21: Depression, Anxiety and Stress Scales;
HADS: Hospital Anxiety and Depression Scale; LASA: Linear Analogue Self -Assessment; MBCB: Montgomery-Borgatta Caregiver Burden; POMS: Prof ile of Mood States; RCT:
randomised controlled trial; SF-36: 36-item Short Form; STAI: State-Trait Anxiety Inventory.
GRADE Working Group grades of evidence
High certainty : we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty : we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty : we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aDif ferent populat ions (e.g. m ixed cancer caregiver samples, paediatric or adult (or both) caregiver samples).
bDif ferent intervent ions.
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cOne quasi-RCT included.
dOutcomes measure sim ilar constructs but do not completely overlap.
eSmall number of neuro-oncology caregivers.
fOnly long-term ef fects reported (six to eight months post baseline).
gHigh attrit ion, analysed using last observat ion carried forward in one study.
hOnly included parents of children with brain tumours.
iOne study with inadequate sequence generat ion and allocat ion concealment.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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B A C K G R O U N D
Description of the condition
The diagnosis and treatment of a brain or spinal cord tumour
can have a huge impact on the lives of patients and their families.
Approximately 28 per 100,000 adults aged 20 years and over are
affected by central nervous system tumours, with the majority
of tumours (approximately 66%) being non-malignant (Ostrom
2014). In children and young adults under 19 years of age, central
nervous system tumours are the most common tumour, with an
annual age-adjusted incidence rate of 5.4 per 100,000 (Ostrom
2014).
The treatment and expected outcome depend heavily on the tu-
mour type, molecular markers, tumour grade, and location. Treat-
ment generally consists of surgical intervention, radiotherapy, che-
motherapy, or a combination of treatment methods. In making
treatment decisions, benefit from treatment is weighed against the
expected quality of life (QoL) and symptom burden of patients.
Depending upon the tumour location and treatment adverse ef-
fects, patients can experience neurological symptoms such as weak-
ness, sensory loss, and motor dysfunction, or visual-perceptual
deficits and problems with speech and language (Mukand 2001).
Cognitive deficits such as problems with memory and concen-
tration occur in most patients, and epilepsy is also common
(Armstrong 2016a; Durand 2015; van Loon 2015). Moreover, fa-
tigue, depression, and changes in personality and behaviour are fre-
quently reported throughout the course of the disease (Armstrong
2016b; Cavers 2012; Rooney 2011). These symptoms can influ-
ence the degree to which patients can participate in vocational
and social activities and can prevent independence and affect QoL
(Aaronson 2011; Klein 2001; Macartney 2014).
Patients commonly come to rely on their family caregivers (e.g.
spouses, family members, or close friends) for both physical and
emotional support. Consequently, many family caregivers expe-
rience considerable burden and distress, and consistently report
feeling ill-prepared for their caregiving role (Choi 2012; Sterckx
2013). Therefore, interventions to support caregivers are expected
to help the caregiver, the patient, and the family unit.
Various studies have explored the needs of family caregivers in
neuro-oncology, and showed a desire for clear information and
communication with healthcare professionals, concerning manag-
ing patients’ symptoms, treatment, and available resources; health
service needs and care co-ordination; and the need for psycho-
logical and social supportive care options (Moore 2012; Sterckx
2013).
Description of the intervention
Individual caregivers’ needs can vary greatly depending on the pa-
tient’s time point in treatment, the caregiver’s social support sys-
tem, expectations and experienced burden (i.e. the stress experi-
enced as a result of the home care situation) (Ownsworth 2015a).
Therefore, any intervention programme aimed at improving the
well-being of family caregivers in neuro-oncology was considered
for this review. Here, the term ’well-being’ encompassed all aspects
of QoL, psychological distress, coping, and mastery (i.e. the feel-
ing of being in control of the caregiving situation).
The interventions under investigation included, but were not
limited to, programmes aimed at supporting family caregivers
through:
• improving information provision (e.g. what to expect from
their role as a family caregiver; teaching caregivers what the
treatment options are; and educating them on supportive care
options);
• caregiver skills training (e.g. how to recognise (changes in)
patients’ symptoms; how to manage symptoms or improve
patients’ everyday functioning); and
• psychosocial support (e.g. psychosocial interventions to
help caregivers cope better; therapeutic interventions to promote
a healthy relationship between the patient and caregiver;
bereavement support after the patient has died).
Following the National Institute for Health and Care Excellence
(NICE) recommended model of psychological assessment and
support (NICE 2004), interventions could be any from level 1
(information and general support given by any health and social
care professional - or self-help) to level 4 (specialist psychologi-
cal or psychiatric interventions delivered by mental health profes-
sionals). We did not expect effectiveness of interventions to vary
within different subgroups of caregivers (e.g. grade of tumour and
age of patient). The interventions were not expected to pose a
risk to caregivers; however, length or complexity of intervention
programmes may have increased caregiver burden and could have
caused caregivers to feel overwhelmed instead of supported.
How the intervention might work
Supportive interventions for family caregivers in neuro-oncology
may help in various ways.
Improving information provision and caregiver skills training can
help prepare family members and friends for their caregiving role
and activities. When caregivers learn more about the disease and
its symptoms, they feel more confident in distinguishing between
which (changes in) symptoms could be normal or expected and
which may require medical follow-up. Through this mechanism,
patient outcomes may be improved as better symptom manage-
ment is initiated sooner and new tumour activity may be detected
earlier in the disease trajectory, allowing treatment to commence.
Moreover, symptoms may be recognised and treated before be-
coming more serious and requiring inpatient treatment, thus po-
tentially reducing healthcare costs. Finally, increasing caregivers’
confidence in dealing with the care situation can substantially im-
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prove their feelings of mastery. This may have a positive effect on
their overall well-being, their QoL, and the quality of care they
deliver in the home situation.
Psychosocial support can provide caregivers with the tools to im-
prove coping strategies to deal with the psychological burden of
being a caregiver to a person who has been diagnosed with a brain
or spinal cord tumour. Many patients and caregivers struggle with
maintaining a healthy relationship, particularly after changes in
the patient’s personality and behaviour, and psychological sup-
port to caregivers or patient-caregiver dyads can help couples work
through these issues together. It is known that patients who go
through divorce or separation are more likely to be hospitalised
and less likely to complete treatment, become involved in clinical
trials, or die at home (Glantz 2009). Therefore, promoting healthy
patient-caregiver relationships may have a positive effect on long-
term patient outcomes. This can help decrease caregivers’ levels
of distress and burden. As many caregivers will provide care for a
longer period of time, up to many years on end, decreasing distress
and burden may prove beneficial as the physical consequences of
long-term high levels of stress may be prevented. Finally, main-
taining good physical as well as emotional health in caregivers will
allow them to continue their caregiving tasks, which will benefit
patients as well.
Why it is important to do this review
Meeting the needs of family caregivers in neuro-oncology, by de-
creasing their distress and burden and improving their sense of
mastery, is imperative in order to maintain their emotional and
physical health. Protecting caregivers’ QoL can enable them to
continue their caregiving activities to maintain the best possible
level of patients’ well-being. Indeed, caregiver support is listed as
a top research priority in neuro-oncology in the UK through the
James Lind Alliance Priority Setting Partnership (Grant 2015).
Furthermore, the UK National Health Service (NHS) has made
several commitments to caregivers, including supporting care-
givers’ mental health and well-being alongside physical needs
(NHS England 2014).
Information and support for caregivers of patients with brain and
spinal cord tumours is becoming more widely available and care-
giver programmes are becoming more common in clinical practice
in some centres. Specialised nurses who may also provide caregiver
support corresponding with level 1 of the NICEmodel of psycho-
logical support (NICE 2004), are in many countries part of the
treatment team. However, large-scale implementation of caregiver
support may be hindered by the lack of high-quality evidence for
the effects of caregiver interventions in populations of brain and
spinal tumour patients. Indeed, one report from Macmillan Can-
cer Support revealed that more than half of family caregivers in
oncology did not receive support at present (Macmillan/You Gov
2016). This systematic review will provide an overview of care-
giver interventions for those taking care of patients with a brain or
spinal tumour, assessed in randomised controlled trials (RCTs). It
will also provide a brief economic summary of the health economic
benefits where these have been measured. It is expected that this
will be useful to make recommendations for policy and practice.
O B J E C T I V E S
To assess the effectiveness of supportive interventions at improving
the well-being of caregivers of people with a brain or spinal cord
tumour. To assess the effects of supportive interventions for care-
givers in improving the physical and emotional well-being of pa-
tients with a brain or spinal cord tumour and to evaluate the health
economic benefits of supportive interventions for caregivers.
M E T H O D S
Criteria for considering studies for this review
Types of studies
RCTs and quasi-RCTs. We included trials that used quasi-ran-
domised methods if there was sufficient evidence that the treat-
ment and control groups were similar at baseline. If this was un-
clear, we contacted trial authors to request clarification.
Types of participants
Studies with adult caregivers (aged 18 years or older) for people
with a brain or spinal cord tumour. The people for which they
provide care could have been of any age, with any type of malig-
nant or non-malignant, primary or secondary brain or spinal cord
tumour, at any time during the disease trajectory.
Types of interventions
Any type of intervention whose primary aim was to improve care-
giver well-being. We included trials that evaluated the effective-
ness of individual- and group-based interventions for caregivers
or for patient-caregiver dyads as long as they reported caregiver
outcomes. We placed no restrictions on: the setting (e.g. hospi-
tal, clinic, psychologist office, at home, or elsewhere); the facil-
itator of the intervention (e.g. a healthcare professional (includ-
ing nurse specialists), social worker, or (guided) self-help); or the
method of delivery of the intervention (e.g. delivered face-to-face,
online, written, or by telephone). Thus, interventions could reflect
any level of psychological support from the NICE model (NICE
2004). Any control condition was acceptable (e.g. wait list control
7Interventions to help support caregivers of people with a brain or spinal cord tumour (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
groups, attention-only control groups, and information-only con-
trol groups). We contacted trial authors if it was unclear whether
a trial met our inclusion criteria.
Types of outcome measures
For all primary outcomes, we accepted recognised caregiver ques-
tionnaires or instrumentsmeasuringmood, caregiver burden,mas-
tery, marital adjustment, QoL, and physical functioning. Where
measured, we assessed the effect on patient emotional and physi-
cal well-being patient questionnaires under Secondary outcomes.
Acceptable outcomes are listed below.
Primary outcomes
Outcomes related to caregiver emotional or physical well-
being
• Psychological distress (depression and anxiety) (e.g.
Hospital Anxiety and Depression Scale (HADS; Crawford
2001), Center for Epidemiological Studies Depression Scale
(CES-D; Radloff 1977)).
• Caregiver burden (e.g. Caregiver Reaction Assessment
(CRA; Given 1992)).
• Caregiver mastery (e.g. Mastery Scale (Pearlin 1978)).
• Quality of patient-caregiver relationship (e.g. Locke-
Wallace Short Marital Adjustment Test for spousal relationships
(Jiang 2013)).
• Quality of life (QoL), either caregiver specific (e.g.
Caregiver QoL index-cancer (CQOLC; Weitzner 1999),
Caregiver Oncology QoL Questionnaire (CarGOQoL; Minaya
2012), or generic, e.g. Short Form Health Survey (SF-36;
McHorney 1993), EuroQol (EQ-5D Brooks 1996)).
• Physical functioning (e.g. number of chronic conditions
present, physical measures of stress levels (e.g. cytokines),
physical subscales of QoL questionnaires).
Secondary outcomes
Outcomes related to patient emotional or physical well-being
• Psychological distress (depression and anxiety) (e.g. HADS
(Crawford 2001), CES-D (Radloff 1977)).
• QoL (e.g. European Organization for Research and
Treatment of Cancer QLQ-C30 (EORTC QLQ-C30; Aaronson
1993); Functional Assessment of Cancer Therapy (FACT;
Weitzner 1995), 36-item Short Form Health Survey (SF-36;
McHorney 1993)).
• Symptom management, number or severity (or both) of
symptoms (e.g. measured with MD Anderson Symptom
Inventory-Brain Tumor Module (MDASI-BT; Armstrong 2006),
EORTC Brain Cancer Module (EORTC QLQ-BN20;
Taphoorn 2010)).
• Number of visits to the emergency department (e.g. as
detailed in medical records).
• Number and length of hospitalisations (e.g. as detailed in
medical records).
Outcomes related to the health economic effects
• Caregiver or patient (or both) employment status (e.g. self-
reported).
• Productivity loss at work of caregiver or patient (or both)
(e.g. self-reported).
• Caregiver healthcare utilisation for acute or chronic (or
both) conditions (e.g. self-reported or as detailed in caregiver’s
medical records).
We included trials with different outcomes to those mentioned
above, when they measured the same construct.
Search methods for identification of studies
There were no restrictions based on type of publication, year of
publication, or language. We considered both published and un-
published RCTs.
Electronic searches
We searched the following databases on 24 August 2018:
• the Cochrane Central Register of Controlled Trials
(CENTRAL; 2018, Issue 7), in the Cochrane Library, using the
search strategy in Appendix 1;
• MEDLINE via Ovid (1946 to August week 3 2018), using
the search strategy in Appendix 2;
• Embase via Ovid (1980 to 2018 week 34), using the search
strategy in Appendix 3.
We also searched ClinicalTrials.gov (clinicaltrials.gov/).
Searching other resources
We handsearched the references of identified studies for studies
that were not identified through the electronic search.
We searched conference abstracts and proceedings from 2013 to
2018 through the American Society of Clinical Oncology (ASCO;
www.asco.org/ASCO/Meetings), the Society for Neuro-Oncol-
ogy (SNO; supplements of Neuro-Oncology; academic.oup.com/
neuro-oncology), and the International Psycho-Oncology Society
(IPOS; special issues of Psycho-oncology).
We handsearched the two main journals in the field of neuro-on-
cology, Neuro-oncology and Journal of Neuro-oncology, for publica-
tions from 2017 that were not identified through the electronic
search.
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We contacted the authors of publications known to focus on im-
proving the well-being of caregivers of patients with a brain or
spinal cord tumour, to enquire about unpublished or ongoing tri-
als. These additional searches were completed on 20 July 2017 (for
the initial search) and 23 January 2019 (for the updated search).
Data collection and analysis
Full details on planned data collection and analysis are available
in the published protocol (Boele 2017a).
Selection of studies
Two review authors (FB and AR) selected studies for inclusion.
After removing duplicates, the two review authors independently
screened all titles and abstracts. We excluded studies that did not
meet the inclusion criteria while storing these discarded studies in
a file as potentially relevant.We retrieved full-text reports and sub-
jected the eligible studies to further assessment. We documented
reasons for exclusion and resolved disagreements between review
authors by discussion. If the published report contained too little
information to assess the trial, one review author (FB) contacted
the study authors to request further details.
Data extraction and management
Two review authors (FB and AR) examined each selected report
and extracted data using a data collection form based on Cochrane
Consumers andCommunication’sGroup data extraction template
(Cochrane CCG 2016). This data collection form included par-
ticipant characteristics (e.g. age, sex, group size, patients’ tumour
type, grade, disease stage, etc.) and information about the sup-
portive intervention (e.g. method, duration, delivery, provider);
the time points at which the outcomes were assessed; whether
outcomes were self-reported or other; whether the tool was vali-
dated; how missing data were handled; statistical methods used;
and whether these were appropriate. The form also included de-
tails on the results (continuous outcomes: mean difference (MD)
and standard error (SE), number of participants; dichotomous
outcome data: e.g. number of caregivers who showed an improve-
ment in terms of emotional or physical well-being as a proportion
of the total number treated; and other results e.g. MD, odds ratio,
risk difference, confidence intervals (CI), P values), and informa-
tion on adherence and attrition (Chandler 2013).
Assessment of risk of bias in included studies
The two review authors responsible for the selection of studies
and data extraction assessed the risk of bias in accordance with the
Cochrane tool for assessing risk of bias (Higgins 2011a). This in-
cluded several domains: random sequence generation; allocation
concealment, blinding of participants and personnel, blinding of
outcome assessment, incomplete outcome data, and selective re-
porting. The risk of bias was categorised as high, low, or unclear.
’High risk’ was selected if there was a non-random component
(random sequence generation); if participants or investigators en-
rolling participants could possibly foresee assignment which could
introduce selection bias (allocation concealment); if participants
and personnel were not completely blinded and the outcome was
likely to be affected by lack of blinding (blinding of participants
and personnel); if there was no blinding of outcome assessment
and outcomemeasurementwas likely to be influenced (blinding of
outcome assessment); if the reason for missing data was likely re-
lated to true outcome with either imbalance in numbers or reasons
for missing data across groups, if the results for missing outcomes
likely induced clinically relevant bias, if participants in ’as treated’
analysis did not receive the intervention as planned, or if sim-
ple imputation was inappropriately applied (incomplete outcome
data); if not all prespecified outcomes were reported or outcomes
were reported using measurements, analysis methods or subsets
of the data that were not prespecified (selective reporting). The
risk of bias in the included studies was discussed between review
authors.
Measures of treatment effect
For dichotomous outcome data, we aimed to abstract the number
of caregivers who showed an improvement in terms of emotional
or physical well-being as a proportion of the total number treated.
We aimed to calculate and present risk ratios (RRs) with 95% CIs.
For continuous outcome data from studies using the same in-
strument, we aimed to estimate MDs between treatment groups.
Where different instruments were used, we aimed to calculate
the standardised mean difference (SMD) by dividing the MD
in postintervention scores between the intervention and control
groups by the standard deviation (SD) of the outcome among par-
ticipants. We aimed to present both the MD and SMDwith 95%
CIs for individual outcomes in individual studies. If these data
were unavailable, we contacted study authors to request additional
information, and if still unavailable, we presented the reported
significance levels instead.
Unit of analysis issues
Different levels of randomisation (e.g. at the level of participants
or groups) were taken into account. When there were long-term
follow-up assessments available within trials, we aimed to analyse
outcomes for two different follow-up categories: short term (i.e.
zero to three months); or medium to long term (i.e. four months
andmore). If studies with multiple intervention groups were iden-
tified, we aimed to make pair-wise comparisons between all pos-
sible pairs of intervention groups. We aimed to make efforts not
to double-count participants in the analysis.
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Dealing with missing data
We contacted the corresponding authors of the trials in writing
to request missing data. We evaluated the reporting of important
numerical data such as the number of screened and randomised
participants, and whether intention-to-treat or per-protocol anal-
yses were done. Missing data were not imputed (Higgins 2011a).
Assessment of heterogeneity
We planned to assess the impact of the heterogeneity of included
intervention studies with the I2 statistic for each outcome (Higgins
2011b). Substantial heterogeneity would be defined as I2 greater
than 50% and forest plots were to be visually inspected for het-
erogeneity. In the case of meta-analysis being possible, we planned
to use a random-effects model as a certain degree of heterogeneity
was expected.
Assessment of reporting biases
We planned to draw funnel plots of treatment effect versus pre-
cision with the data from all studies (Higgins 2011b), if at least
10 studies were identified. The funnel plots were to be visually
inspected to assess whether there was selective reporting of out-
comes.
Data synthesis
If trials included different outcomes, we aimed to pool outcomes
that measured the same construct, or systematically report on out-
comes that did not measure the same construct.
We aimed to perform a meta-analysis if we found two or more
RCTs with a low risk of bias in which study population, interven-
tion, and outcome measures were comparable. With meta-analy-
sis not possible, two review authors (FB and HB) synthesised the
findings of the included studies in Summary of findings for the
main comparison, and rated the overall certainty of the evidence
according to the GRADE levels of evidence (Higgins 2011a; Ryan
2016).
Subgroup analysis and investigation of heterogeneity
If sufficient studies were identified (i.e. at least two for each sub-
group), we had planned to perform subgroup analyses for the study
design (RCT or quasi-RCT), the type of intervention, the type
of control group, timing (e.g. shortly after the patient’s diagnosis,
during initial antitumour treatment, following initial treatment,
in the palliative phase or during the bereavement phase), and pa-
tient tumour type.
Sensitivity analysis
If sufficient datawere available, we planned to perform a sensitivity
analysis to assess the robustness of results (e.g. excluding studies
with high risk of bias).
R E S U L T S
Description of studies
See Characteristics of included studies; Characteristics of excluded
studies; and Characteristics of ongoing studies tables.
Results of the search
A flowchart of our search is shown in Figure 1. The initial search
yielded 1670 records, supplemented by 413 records found in elec-
tronic database searches and handsearching conference abstracts
and proceedings from 2013 to 2018, as well as publications in
Neuro-oncology and Journal of Neuro-oncology from 2017. After
removing duplicates, 1666 records remained. Upon screening of
titles and abstracts, results were narrowed down to 122 records.
Of these, 117 were excluded: 50 records were not (quasi) RCTs;
27 studies did not aim to improve caregiver well-being; 13 were
not focused on caregivers or (or both) neuro-oncology; 15 were
duplicates; four were published protocols only. Thirteen stud-
ies were potentially eligible and we requested additional infor-
mation from the authors. Four publications included less than
20%of neuro-oncology caregivers in their samples (Cernvall 2015;
Hudson 2015; Kissane 2016;Mooney 2015), making it debatable
whether the outcomes would be generalisable to the neuro-oncol-
ogy caregiver population. There were four ongoing trials (Halkett
2015; Langbecker 2016; Ownsworth 2015b; Roberge 2016).
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Figure 1. Study flow diagram. RCT: randomised controlled trial.
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The search update yielded a further 413 references. Publications
and conference abstracts were also screened at this time. In total,
the search update produced 436 records. Of these, 22 were re-
viewed in detail, and 19 were excluded: 13 records were not (quasi)
RCT; two did not aim to improve caregiver well-being, and three
included less than 20% neuro-oncology caregivers, or an unclear
percentage (Epstein 2017; Holm 2016; Lawsin 2017). There was
one ongoing trial (NCT03454295). Three additional trials were
thus included after the search update.
Eight publications were included in the review.
Included studies
See Characteristics of included studies tables.
Design and setting
Seven studies were RCTs (Andela 2017; Boele 2013; Dionne-
Odom 2015; Klosky 2007a; Reblin 2018; Safarabadi-Farahani
2016; Wakefield 2016), another was quasi randomised as the last
three participants were allocated to the intervention group auto-
matically (Locke 2008). In four publications, randomisation took
place at the level of the family or patient-caregiver dyad (Andela
2017; Dionne-Odom 2015; Klosky 2007a; Locke 2008). In one
study, both parents could participate and were then assigned to
the same condition, but in different groups (Wakefield 2016). In
three studies, caregivers were randomised at the individual level by
themselves (Boele 2013; Reblin 2018; Safarabadi-Farahani 2016).
Four trials took place in the US (Dionne-Odom 2015; Klosky
2007a; Locke 2008; Reblin 2018), one in Australia (Wakefield
2016), two in the Netherlands (Andela 2017; Boele 2013), and
one in Iran (Safarabadi-Farahani 2016).
Participant demographics
The total sample sizes for the included studies ranged from 19
(Locke 2008) to 122 (Dionne-Odom 2015) randomised partici-
pants. However, not all eight studies exclusively focused on neuro-
oncology caregiver populations. We included studies only if more
than 20% of caregivers in the sample were taking care of a patient
with a primary or secondary brain or spinal cord tumour. As a
result, the sample size for the subset of participants of interest to
this review were smaller, ranging from 13 (29% of the sample;
Wakefield 2016) to 56 (100% of the sample; Boele 2013) neuro-
oncology family caregivers. Participant demographics were only
available for the total samples of the included studies. Two studies
did not report on caregiver demographics (Klosky 2007a; Locke
2008). Participants’ mean age ranged from 42 years (Wakefield
2016) to 61 years (Dionne-Odom 2015). In all studies except
one (Andela 2017 (44%)), the majority of caregivers were female
(ranging from 64% of the total sample in Boele 2013 to 95% in
Safarabadi-Farahani 2016). Of note, three studies focused on fam-
ily caregivers of children diagnosed with cancer (Klosky 2007a;
Safarabadi-Farahani 2016; Wakefield 2016); the other five studies
only included those taking care of an adult (Andela 2017; Boele
2013; Dionne-Odom 2015; Locke 2008; Reblin 2018). Only
one study included a significant proportion of caregivers taking
care of a patient with secondary brain tumours (brain metastases;
Dionne-Odom 2015).
Intervention characteristics
Four of the interventions focused on patient-caregiver dyads (
Andela 2017; Dionne-Odom 2015; Klosky 2007a; Locke 2008),
four aimed to improve specifically caregiver well-being and did not
involve the patient directly (Boele 2013; Reblin 2018; Safarabadi-
Farahani 2016; Wakefield 2016).
Caregiver-focused interventions
The intervention tested by Boele 2013 was based on the prin-
ciples of cognitive behavioural therapy (CBT) and psychoeduca-
tion. Once every two weeks, for a total of six sessions, a psychol-
ogist would meet with the caregiver. During the first session, the
caregiver and psychologist reviewed the issues and needs of the
caregiver. During the second session, an introduction of the in-
tervention and rationale behind CBT was given. A selection of
topics was available for the other four sessions: 1. contact with the
patient; 2. the direct environment (contact with family, friends,
and other); 3. epilepsy; 4. changes in behaviour, character, and
cognition; 5. time for yourself; 6. children (what and how to tell
them); and 7. practical and emotional care in the end of life phase.
The participants in the control group received care as usual.
Reblin 2018 tested a web-based intervention called eSNAP, which
aimed to help caregivers visualise their existing social network re-
sources. Users were able to list people and groups who could help
within six categories of support: 1. hands on; 2. informational; 3.
communication; 4. financial; 5. emotional; and 6. self-care. A vi-
sualisation of the support network was created based on caregivers’
input and printed in PDF. The intervention was completed within
one session (taking approximately 10 to 15 minutes), while wait-
ing for the patient’s hospital appointment, and the visualisation
report could be revisited by caregivers if they wished. Participants
in the control group received care as usual.
The Brief Psychological Intervention (BPI) tested by Safarabadi-
Farahani 2016 employed problem-solving skills training and psy-
choeducation. In five sessions lasting between 60 and 90 minutes,
a trained social worker covered the following aims: 1. engage and
motivate caregivers to participate and develop open communi-
cation with the social worker; 2. develop an optimistic attitude,
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maintaining hope and focus on achievable short-term goals; 3.
provide information about treatments and medication, and liv-
ing with uncertainty; 4. help caregivers cope with stress and teach
stress-reducing techniques, coping strategies, and promote healthy
lifestyle behaviours; and 5. education of self-care strategies. Ses-
sions were followed up with a telephone call (five in total). The
control group participants received care as usual, including coun-
selling and financial support.
The Cascade programme tested by Wakefield 2016 was based
on the Uncertainty in Illness model and Family-Systems-Illness
model. The three-week programme consisted of weekly 120-
minute online sessions delivered by a psychologist throughWebEx.
After each session, caregivers would get homework assignments to
practice. The programme intended to target intra- and interper-
sonal psychological processes that are important to adaptation in
the context of illness (e.g. acceptance of uncertainty). CBT strate-
gies were used to target these core mechanisms of change. The
topic areas were not specified in the publication. Control group
participants could participate in the Cascade programme after a
six-month waiting list period.
Patient-caregiver dyadic interventions
Andela 2017 tested the ’Patient andPartner EducationProgramme
for Pituitary disease’ (PEPP-pituitary). This was based on a stan-
dardised self-management programme originally developed for
Parkinson’s disease, and supplemented with information for fa-
tigue, cognitive complaints, and problems with sexuality. It ad-
dressed psychological and social issues related to the disease and
used techniques from CBT such as cognitive restructuring, situ-
ational behavioural analysis, social skills training, and relaxation
training. The eight-week programme consisted of 90-minute ses-
sions guided by a psychologist or medical social worker. Patients
and caregivers participated in separate groups of five to seven par-
ticipants. The sessions were titled: 1. information; 2. self-monitor-
ing; 3. health promotion; 4. stress management; 5. management
of anxiety and depression/caregivers’ challenge; 6. social compe-
tence; 7. social support; and 8. evaluation. Control group partic-
ipants could take part in a single (optional) information meeting
in week four or five and were given the option to take part in the
PEPP-pituitary programme after the last assessment.
Dionne-Odom 2015 tested a dyadic intervention in the ENABLE
III (Educate, Nurture, Advise, Before Life Ends III) trial. Based
on their earlier ENABLE II palliative care intervention and ex-
ploratory interviews with family caregivers, caregivers were more
closely involved in the new trial. The COPE framework (Creativ-
ity, Optimism, Planning, Expert Information) was applied in de-
veloping this coping skills intervention. In three weekly structured
educational sessions, two different palliative care nurses supported
both caregiver and patient. For caregivers, the first session cov-
ered the role of the caregiver, a definition of palliative and sup-
portive care, and an introduction of problem-solving using the
COPE framework. The second session covered caregiver self-care
and effective partnering in patient care. The final session addressed
building a support network, decision making and support, and
advance care planning. At least once a month, the nurse would
follow-up with telephone calls until patient death or study end. If
the patient died during the study, a bereavement call was made.
After a waiting list period of three months, participants in the
control group could take part in the programme as well.
The programme tested byKlosky 2007a was based onCBTprinci-
ples. During radiotherapy simulation, families randomised to the
intervention group received a CBT-based programme including
exposure to an interactive-educational ActiMates Barney, an edu-
cational video in the clinic room including filmed modelling, and
passive distraction via Barney-narrated stories delivered during the
simulation procedure. Families randomised to the control group
received a similar intervention with exposure to a non-interactive
children’s character, an age-appropriate cartoon video picked by
the child, and stories delivered via cassette tape during simulation.
Locke 2008 tested a dyadic intervention based on cognitive reha-
bilitation and problem-solving. In six sessions in a two-week pe-
riod, a psychologist or behavioural therapist taught dyads to use a
calendar that had a specific format as an external aid to compensate
for cognitive symptoms. A model of stress was taught as well as
specific positive problem-solving techniques for its management.
Potential disease-related problems were covered (e.g. adverse ef-
fects, psychological distress, family issues, and sexual issues).
Primary and secondary outcomes
Caregiver-focused interventions
Boele 2013 assessed the primary outcomes of caregiver mastery
(Caregiver Mastery Scale) and QoL (SF-36 Mental Component
Summary) at baseline, two, four, six, and eight months’ follow-up.
Caregivers also completed questionnaires on patient functioning
(QoL (SF-36); Medical Outcome Study (MOS) Subjective Cog-
nitive Functioning scale; EORTC brain cancer module). Health
economic effects were not assessed.
In Reblin 2018, the primary outcome was feasibility. They also
assessed caregiver burden (Zarit Caregiver Burden Scale) and dis-
tress (HADS) at baseline, three weeks, and six weeks’ follow-up.
Caregiver completion of the intervention and satisfaction was also
assessed. No patient well-being or health economic outcomes were
included.
Safarabadi-Farahani 2016 assessed caregiver QoL (Caregiver QoL
Index - Cancer, Persian version) at baseline, postintervention, and
30 days’ follow-up. This questionnaire measured four scale scores:
mental/emotional burden, lifestyle disruption, positive adapta-
tion, and financial concerns, as well as an overall QoL score. Out-
comes related to patient well-being or health economic effects were
not included.
Wakefield 2016 were primarily interested in assessing feasibility
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(response and attrition rates, participant preference for interven-
tion and questionnaire length; therapist’s clinical impressions and
technical difficulties) and acceptability (California Psychotherapy
Alliance Scale-Group short version; Youth Satisfaction Question-
naire). Caregiver QoL (QoL - Family Caregiver Tool), psycholog-
ical functioning (Depression Anxiety Stress Scale (DASS) Short
Form), and family functioning (McMaster Family AssessmentDe-
vice) were also assessed. Caregivers completed questions at base-
line, two weeks, and six months. Outcomes related to patient well-
being or health economic effects were not included.
Patient-caregiver dyadic interventions
Andela 2017 did not specify their primary/secondary outcomes.
Caregiver measures included mood (Visual Analogue Scale -
Mood), self-efficacy (General Self-efficacy Scale), illness percep-
tions (Brief Illness Perception Questionnaire), coping strategies
(Utrecht Coping List), QoL (SF-36), fatigue (Multidimentional
Fatigue Inventory), and anxiety and depression (HADS). Assess-
ments took place at baseline, eight weeks, and six months. Patient
outcomes included all of the above, plus bother and need for sup-
port (Leiden Bother and Needs Questionnaire), participation and
autonomy (Impact on Participation and Autonomy), QoL (EQ-
5D in addition to the SF-36), disease-specific QoL (AcroQol and
CushingQol). Health economic effects were not measured.
Dionne-Odom2015 didnot specifywhichwere their primary/sec-
ondary outcomes. Caregiver QoL (Caregiver QOL Index - Can-
cer), depression (CES-D), and caregiver burden (Montgomery-
Borgatta Caregiver Burden) were reported in the main outcomes
publication. Complicated grief (Prigerson Inventory of Compli-
cated Grief - Short Form; Dionne-Odom 2016) and personality
(Neo-3 Personality Inventory) were also assessed (confirmed via
correspondence). Measurements took place at baseline and every
six weeks until week 24, then every three months until patient
death or student completion. Patient outcomes were reported in
another publication (Bakitas 2015), and included: QoL (Func-
tional Assessment of Chronic Illness Therapy - Palliative Care and
Treatment Outcome Index), symptom impact (QoL at End of Life
symptom impact sub scale), mood (CES-D), one year and overall
survival, resource use and location of death (patient-reported hos-
pital and intensive care unit (ICU) days, emergency department
visits; frommedical record review or proxy reports: decedents’ data
for period between last assessment and death, chemotherapy use
in the last 14 days, location of death).
InKlosky 2007a, caregivers rated their anxiety (State-Trait Anxiety
Inventory (STAI)) and completed a study-specific efficacy ques-
tionnaire. Assessments took place before and after the interven-
tion, which was on the same day. Child outcomes were reported
elsewhere (Klosky 2004; Klosky 2007b; Tyc 2002): a behavioural
observational checklist (modified from Observation Scale of Be-
havioral Distress) as completed by trained clinical observers; heart
rate; sedation; state and trait anxiety (STAI) as completed by par-
ents; and radiotherapy questionnaire to rate parents’ expectations
of their child’s distress during radiotherapy. Health economic ef-
fects were not assessed.
The Locke 2008 study’s primary outcomes were patients’ com-
pensation techniques (Compensation Techniques Questionnaire),
patient and caregiver feedback (study- specific poststudy feedback
questionnaire), and patient QoL and functional capacity (Func-
tional Assessment of Cancer Therapy - Brain, Mayo-Portland
Adaptability Inventory - 4). Secondary outcomeswere patient cog-
nitive functioning (Repeatable Battery for the Assessment of Neu-
ropsychological Status), overall patient and caregiver QoL (Linear
Analogue Self-Assessment scale), caregiver QoL (Caregiver QoL
Index - Cancer), patient and caregiver mood (Profiles of Mood
States (POMS)), and patient fatigue (Brief Fatigue Inventory).
Health economic effects were not assessed. Assessments were done
at baseline, postintervention, and three months’ follow-up.
Statistical analysis
Caregiver-focused interventions
Boele 2013 analysed only the long-term effects (eight months’ fol-
low-up).Missing data (42.9%) were handledwith the last observa-
tion carried forward method, missing data fromwithin completed
questionnaires were not imputed. All participants were included
in analysis following the intention-to-treat principle. Delta scores
for change in caregiver mastery and mental functioning were cal-
culated and entered into a multivariate linear regression model
together with patient’s QoL, cognitive functioning, and neurolog-
ical functioning.
Reblin 2018 used mixed models to analyse differences in distress,
burden, and social support between the intervention group and
control group at three and six weeks’ follow-up, corrected for base-
line scores. Attrition at three weeks was 7.5% (three participants
dropped out in the intervention group; confirmed via correspon-
dence), and was 20% at six weeks’ follow-up. Missing data from
within completed questionnaires were not imputed (confirmed via
correspondence).
Safarabadi-Farahani 2016 checked for baseline differences in so-
ciodemographic variables and QoL scores using Chi2 and t-tests.
Repeated measures analysis of variance was done to compare QoL
scores at postintervention and 30 days’ follow-up between the in-
tervention and control group. This was not corrected for baseline
scores. Questionnaires were checked by the research team directly
after completion, resulting in no missing data (confirmed via cor-
respondence).
Wakefield 2016 was a pilot study and not powered to evaluate
the efficacy of the intervention. Preliminary analyses using a two
(group: intervention versus waiting list) by three (time point: base-
line versus postintervention versus follow-up) mixed analysis of
variance were performed following the intention-to-treat princi-
ple. Caregivers who did not complete all three assessments were
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excluded from the psychosocial outcomes analysis. It is not clear
how the authors handled missing data.
Patient-caregiver dyadic interventions
Andela 2017 compared mood ratings at pre- and postintervention
with paired sample t-tests. Linear mixed models with random par-
ticipant effect and fixed time and group effects were used to assess
the effects of the intervention at eight weeks’ and six months’ fol-
low-up, taking into account missing data (35% in caregivers). Post
hoc analyses (linear mixedmodels) were performedwith data from
participants who attended at least six out of eight sessions (52%
of caregivers). P values of 0.05 were considered statistically signif-
icant, but Bonferroni corrections were also applied (P < 0.005).
Dionne-Odom 2015 performed two longitudinal, intention-to-
treat analyses. First, between-group differences in change from
baseline to three months were examined for caregiver QoL, de-
pressed mood, and burden. In the second analysis, data from care-
givers of whom the patient had died were examined in a terminal-
decline model with all data from the last 36 weeks of the patient’s
life. The exact statistical methods used are not specified further.
The report stated that patterns of missing data were analysed and
the authors referred us to another publication for further informa-
tion (Bakitas 2015). Here, it is stated that maximum likelihood
estimates were used to handle missing outcome data; however, it
was unclear if the statistical methods applied would have been the
same.
Klosky 2007a did not include a statistical methods paragraph;
however, themain outcomes seem to be analysed using t-tests with
a one-sided P < 0.05 as level of statistical significance. In email
correspondence, the authors stated that the statistical methods
should be included in the other publications on the same trial
(Klosky 2004; Klosky 2007b; Tyc 2002).
The pilot study by Locke 2008 was primarily aimed at assessing
the feasibility of the intervention. Recruitment rates, use of taught
strategies, and patient satisfaction were analysed using descriptive
statistics. Patient QoL and functional capacity were analysed using
Wilcoxon signed rank tests (scores from the same group at different
time points) and Wilcoxon rank sum tests (scores from different
groups at the same time point). All other outcomes including
caregiver outcomes were only displayed with descriptive statistics.
Excluded studies
See Characteristics of excluded studies table. Three studies were
identified that met the inclusion criteria, but did not include a
large enough proportion of family caregivers of patients diagnosed
with a primary or secondary brain tumour. For the purpose of
this review, the cut-off was set at 20% of the sample. Four further
studies would potentially qualify but authors did not provide us
with the number of family caregivers of brain tumour patients.
A 10-week online guided self-help programme based on CBT was
tested in a Swedish population of parents of children on can-
cer treatment (Cernvall 2015; Cernvall 2017). The study showed
promise in reducing post-traumatic stress symptoms in parents.
Parents of children with brain tumours made up 15% of the sam-
ple.
The VOICE (Values and Options in Cancer Care) trial aimed to
improve communication between people with advanced cancer,
caregivers, and oncologists (Epstein 2017). Significant improve-
ments in doctor-patient communication were found. The authors
explained the study is likely to have included caregivers of patients
with primary or secondary brain tumours. However, it was unfea-
sible for the local team to retrieve exact numbers.
Holm2016 tested a psychoeducational group intervention in fam-
ily caregivers of patients in specialised palliative home care in Swe-
den. Preparedness for caregiving improved in 55% of participants
randomised to the intervention (Holm 2017). We contacted the
authors to enquire about the numbers of caregivers of patients
with a brain or spinal cord tumour, but received no reply.
In an effort to prepare caregivers for the role of supporting patients
with advanced cancer receiving home-based palliative care, a three-
armRCTwas initiated comparing a one-to-one psychoeducational
intervention with one or two visits, and a care as usual control
group (Hudson 2013; Hudson 2015). There were no reductions
in unmet needs or improvements in positive aspects of caregiving,
but the intervention improved caregivers’ level of preparedness
and competence. Caregivers of patients with brain tumours were
included, but only made up 1% of the sample (confirmed via
correspondence).
A family therapy programme was trialled in people with advanced
cancer and their family caregivers, which was continued into be-
reavement (Kissane 2016). Compared with standard care, the pro-
gramme reduced the severity of complicated grief and the devel-
opment of prolonged grief disorder. The authors confirmed via
correspondence that only few, if any, caregivers of patients with a
brain or spinal cord tumour were included (no exact percentage
provided).
In Australia, the ’Rekindle’ programme was tested in a phase II
feasibility study (Lawsin 2017). This online programme aimed to
provide psychosexual support to cancer patients and their partners.
The study was found feasible, with varying levels of participant
engagement with the programme. We contacted the authors to
enquire about the numbers of caregivers of patients with a brain
or spinal cord tumour, but we received no reply.
Finally, an abstract presented at the 2015 IPOS conference focused
on an RCT of an automated remote symptom monitoring inter-
vention versus care as usual for family caregivers providing home
hospice care (Mooney 2015). Family caregivers reported their own
issues as well as patients’ symptoms and received automated tai-
lored coaching. Moderate/high symptoms would generate an alert
to a hospice nurse. Symptom severity decreased and anxiety and
mood improved after the intervention. Family caregivers of pa-
tients with primary or secondary brain tumours made up 9% of
the sample (confirmed via correspondence).
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Ongoing studies
We identified five potentially relevant ongoing studies (Halkett
2015; Langbecker 2016; NCT03454295; Ownsworth 2015b;
Roberge 2016; Characteristics of ongoing studies table).
Risk of bias in included studies
The Cochrane risk of bias score was determined for each trial and
summarised in Figure 2 and Figure 3.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Figure 3. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Allocation
Most studies described a random component in the sequence gen-
eration process. The Locke 2008 publication did not specify the
randomisation technique used and was quasi-randomised, which
introducedbias (high risk of bias). In the Safarabadi-Farahani 2016
study, a teammember would number participants (0 to 65) and al-
ternate allocation to the intervention or control group (confirmed
via correspondence), leading to an increased risk of bias (high risk
of bias). Selection bias may have also been introduced in Boele
2013, as tickets drawn from a concealed box were not numbered
(high risk of bias).
Blinding
Blinding of participants and research personnel was generally not
possible due to the nature of the interventions (high risk of bias).
The person performing the statistical analysis was only blinded in
the Wakefield 2016 and Reblin 2018 studies (low risk of bias). It
was unclear whether the statisticians were blinded in the Locke
2008 and Safarabadi-Farahani 2016 studies (unclear risk of bias).
This may have introduced performance and detection bias.
Incomplete outcome data
The Klosky 2007a study did not have any attrition, with the pre-
and postintervention assessments taking place on the same day
(confirmed via correspondence) (low risk of bias). In Safarabadi-
Farahani 2016, only 4.6% of the sample dropped out in total, all
due to patient death. For all other respondents, data were com-
plete (confirmed via correspondence) (low risk of bias). The other
studies report attrition ranging between 17% and 52%. The Boele
2013 study had the highest levels of attrition which were handled
using the last observation carried forward method. They reported
reasons for dropout (unclear risk of bias). In Andela 2017, 48%
of caregivers did not complete all intervention sessions and there
were 35% missing data in the caregiver group (confirmed via cor-
respondence), which were handled through linear mixed mod-
elling (unclear risk of bias). The Dionne-Odom 2015 reported
about 32% of caregivers did not complete all follow-up assess-
ments. There were no significant associations between attrition
and caregiver characteristics or outcome, with maximum likeli-
hoodmethods used to estimate missing outcome data (unclear risk
of bias). In Locke 2008, 33% of participants did not complete the
intervention, with a 26% dropout at postintervention increasing
to 32%at threemonths. It was not reported howmissing datawere
handled (high risk of bias). In Reblin 2018, 20% of participants
did not complete the six-week follow-up assessment, with no in-
formation provided on reasons for dropout. No imputation was
done within completed questionnaires (less than 10% of data was
missing), hence missingness was only per person (confirmed via
correspondence) (unclear risk of bias). In Wakefield 2016, there
was 17% attrition at six months in the intervention group and
27% attrition in the control group. They did not report reasons
for dropout and included only complete cases in their evaluation
of psychosocial outcomes (high risk of bias).
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Selective reporting
Wakefield 2016 was linked to a published protocol (Wakefield
2015). However, this protocol referred to the follow-up study, not
the pilot. None of the other studies had published protocols avail-
able, leading to an unclear risk of reporting bias. In Boele 2013,
caregiver burden data were collected but not used as many partic-
ipants failed to complete the questionnaire in the intended way
(unclear risk of bias). In the Dionne-Odom 2015 study, person-
ality was assessed but not reported on (unclear risk of bias). The
remaining studies were also at unclear risk of bias.
Effects of interventions
See: Summary of findings for the main comparison
Interventions to help support caregivers of people with a brain or
spinal cord tumour
The heterogeneity of populations and methodologies used in the
included studies hindered pooling of data and, therefore, meta-
analysis was not carried out. See Summary of findings for themain
comparison.
Primary outcomes
Caregiver psychological distress
We found low-certainty evidence that supportive interventions
were more effective than any control condition. Across six stud-
ies, 163 neuro-oncology caregivers were included. Psychological
distress was measured with six outcomes (DASS-21, the Fear of
Recurrence Questionnaire - Family Member, CES-D, HADS,
POMS, or STAI). Three trials reported improvements after the
intervention (Dionne-Odom 2015: early versus delayed palliative
care; CES-D between-group difference changed from baseline:
mean -3.4 (SE 1.5); P = 0.02; d = -0.32; Klosky 2007a: interactive-
educational programme; STAI State change score mean -19.6 (SD
3.3) intervention versusmean -14.5 (SD 2.7) control; Trait change
score mean -13.5 (SD 2.9) intervention versus mean -6.9 (SD 2.6)
control; Andela 2017: self-management programme; HADS Anx-
iety group by time interaction from baseline to six months (MD
score -2.65), HADS depression group by time interaction from
baseline to eight weeks and baseline to six months (MD: eight
weeks: -2.60; six months: -3.47), HADS total score group by time
interaction frombaseline to eight weeks and baseline to sixmonths
(MD: eight weeks: -4.54; six months: -6.51; P < 0.05). Andela
2017 also compared mood (Visual Analogue Scale - Mood) before
and after each session and reported caregivers’ mood improved
significantly after the last three sessions (mean: session six: from
73.00 (SD 6.95) to 77.17 (SD 6.46); P = 0.005; session seven:
from 75.08 (SD 7.32) to 78.15 (SD 7.03); P = 0.025; session
eight: from 73.08 (SD 6.09) to 77.54 (SD 7.66); P = 0.030).
Three feasibility/pilot trials alsomeasured distress. InReblin 2018,
(electronic social network intervention) depression decreased af-
ter the intervention (mean: HADS depression scale: 9.795 with
intervention versus 11.822 with control; F = 3.432; P = 0.072).
There were no effects for anxiety. One trial found no significant
effects (Wakefield 2016: e-mental health intervention; DASS-21;
Fear of Recurrence Questionnaire - Family Member). The other
trial only reported descriptives (Locke 2008; cognitive rehabili-
tation and problem solving), with POMS mean scores being the
same postintervention in both groups. At three months, scores in
control group were higher (mean 74 (SD23.9) with control versus
73 (SD 16.1) with intervention).
Caregiver burden
There was low-certainty evidence that supportive interventions
were not more effective than control conditions. One study that
included a heterogeneous sample of 27 neuro-oncology care-
givers (advanced cancer only; including those taking care of peo-
ple with brain metastases) reported caregiver burden outcomes
(Dionne-Odom 2015). There was no statistically significant dif-
ference between the groups for any of the Montgomery-Borgatta
Caregiver Burden subscales (objective, demand, stress burden). A
pilot study of electronic social network mapping found no differ-
ences over time in caregiver burden (Zarit Caregiver Burden Scale)
between the intervention and control groups (Reblin 2018).
Caregiver mastery
Very low-certainty evidence found that psychological support was
more effective than care as usual. In one study among 56 care-
givers, mastery (Caregiver Mastery Scale) improved in the inter-
vention group compared with the control group (1R2 = 0.055,
P = 0.021), corrected for the confounding factors of changes in
patient’s communication deficits (EORTC QLQ BN-20), cogni-
tive functioning (MOS). and physical functioning (SF-36 Physi-
cal Component Summary) (Boele 2013). Self-efficacy and coping
skills, concepts closely linked to mastery, did not improve in a self-
management programme compared to controls (Andela 2017).
Quality of patient-caregiver relationship
Very low-certainty evidence found that a supportive e-mental
health intervention was not more effective than a waiting list con-
trol condition (Wakefield 2016). This feasibility study, which in-
cluded 13 parents of patients with a childhood brain tumour,
showed no statistically significant difference on the McMaster
Family Assessment Device family communication, problem-solv-
ing, and general functioning subscales.
Caregiver quality of life
We found very low-certainty evidence that supportive interven-
tions were more effective than control conditions. Across six
studies which included 157 neuro-oncology caregivers in total,
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two trials found improvements after intervention (Andela 2017:
self-management programme; SF-36 Vitality sub scale group by
time interaction from baseline to eight weeks and baseline to
six months (MD: eight weeks: 14.03; six months: 15.45; P
= 0.026); Safarabadi-Farahani 2016: psychosocial intervention;
mean CQOLC total, mental/emotional burden, lifestyle disrup-
tion, positive adaptation sub scale scores higher than control group
mean scores over time; all P < 0.001). One trial found stable QoL
(SF-36 Mental Component Summary) in the intervention versus
the control group (psychological support; Boele 2013), which was
no longer statistically significant after controlling for changes in
patient functioning. A trial and a pilot trial found no evidence
for improvements in QoL after the intervention (Dionne-Odom
2015 using CQOLC; Wakefield 2016 using QoL - Family Care-
giver Tool); one pilot trial only reported descriptive results (Locke
2008), with CQOLC scores appearing to improve slightly in both
the intervention group (mean: from 95 (SD 20.1) at baseline to
98 (SD 19.5) postintervention) and control group (mean: from
93 (SD 174) at baseline to 102 (SD 11.7) postintervention).
Caregiver physical functioning
None of the included studies evaluated caregiver physical func-
tioning.
Secondary outcomes
Patient emotional or physical well-being
Psychological distress (depression and anxiety)
There was no support for the effectiveness of caregiver support
on reducing patient psychological distress. Three trials did not
show statistically significant differences (Andela 2017: HADS;
Dionne-Odom 2015 (Bakitas 2015): CES-D; Klosky 2007a:
OBD). Andela 2017 did report improved mood (Visual Analogue
Scale -Mood) after all intervention sessions except the first (before
range: 65.27 to 70.76; after range: 73.11 to 77.93; all changes P
< 0.0015). Klosky 2007a collected further data on STAI scores
but did not report descriptive statistics or between-group changes.
One trial only reported descriptive results, with POMS scores
appearing to improve slightly in the intervention group (mean:
baseline: 65 (SD 24.6); two weeks’ follow-up: 72 (SD 7.0); three
months’ follow-up: 76 (SD 11.3)) and declining slightly in the
control group (mean: baseline: 81 (SD 2.3); two weeks’ follow-
up: 76 (SD 9.4); three months’ follow-up: 79 (SD 8.7)) (Locke
2008).
Quality of life
There was little information for the effectiveness of caregiver sup-
port on improving patient QoL. Three studies found no statis-
tically significant differences between the intervention and con-
trol groups for overall QoL (Andela 2017: EQ-5D, SF-36, Cush-
ingQol, AcroQol; Dionne-Odom 2015: FACIT-Pal; Locke 2008:
FACT-BR), although Locke 2008 reported better scores after the
intervention on the physical well-being sub scale (MD 3.25 95%
CI 0.07 to 6.43; P = 0.04). Furthermore, Locke 2008 reported
descriptive results on LASA scores, which appear to be comparable
between the intervention and control groups over time. One trial
collected further data on proxy-measured patient QoL, but did
not report descriptive statistics or between-group changes (Boele
2013: SF-36).
Symptom management, number or severity (or both) of
symptoms
No support was found for the effectiveness of caregiver support
on patient symptom management. Two studies did not find sta-
tistically significant differences between the intervention and con-
trol groups (Dionne-Odom 2015: QoL at End of Life (QUAL-E)
Symptom Impact sub scale; Locke 2008: Mayo-Portland Adapt-
ability Inventory (MPAI-4)). Two studies assessed patient fatigue.
Andela 2017 (Multidimentional Fatigue Inventory-20) reported
no statistically significant differences. Locke 2008 (Brief Fatigue
Inventory) reporting descriptive results indicating a slight im-
provement in the intervention group over time (mean: baseline:
4.4 (SD 2.5); two weeks’ follow-up: 4.2 (SD 2.7); three months’
follow-up: 3.2 (SD2.8)), whereas scores seemed to improve for the
control group at postintervention (mean: baseline: 2.6 (SD 3.0);
two weeks’ follow-up: 1.8 (SD 1.7)), and then deteriorate again at
threemonths’ follow-up (mean: 3.0 (SD 3.5)). Locke 2008 also as-
sessed neuropsychological functioning (Repeatable Battery for the
Assessment of Neuropsychological Status); however, results were
not presented due to a lack of sufficient follow-up data. One trial
further collected data on proxy-reported patient symptom burden
(Boele 2013: EORTC QLQ-BN20 and MOS Cognitive Func-
tioning scale), but did not report descriptive statistics or between-
group changes.
Number of visits to the emergency department
There was no support for the effectiveness of caregiver support on
the number of patient visits to the emergency department. Only
one trial assessed this outcome (Dionne-Odom 2015). There was
no significant difference between the early and delayed palliative
care groups; however, the rate of resource use appeared to be lower
in the early palliative care group (0.14, 95% CI 0.09 to 0.2) than
in the delayed group (0.19, 95% CI 0.14 to 0.26).
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Number and length of hospitalisations
There was no support for the effectiveness of caregiver support on
the number and length of patient hospitalisations. Only one trial
assessed this outcome and found no significant difference between
the groups (Dionne-Odom 2015). However, hospital visits and
ICU stays were less frequent in the early (rate of hospital days:
0.95, 95% CI 0.61 to 1.46; rate of ICU days: 0.1, 95% CI 0.04
to 0.24) versus delayed palliative care group (rate of hospital days:
1.3, 95% CI 0.91 to 1.86; rate of ICU days: 0.15, 95% CI 0.07
to 0.3).
Other relevant patient well-being outcomes
The self-management programme investigated by Andela 2017
found group by time interactions in patient self-efficacy with im-
provements in the control group (GSEMD: at eight weeks: 1.35;
at six months: 1.74; both P < 0.05). Results for bother and need
for support (various scales of the Leiden Bother and Needs Ques-
tionnaire for patients with pituitary disease (LBNQ-Pituitary))
were variable, showing some improvement at eight weeks after
intervention, yet heightened scores indicating more bother at six
months. Differences from baseline to six months were not statisti-
cally significant. There were no differences for illness perceptions
(Brief Illness PerceptionQuestionnaire (BIPQ)), coping (Utrecht’s
Coping List (UCL)), or participation and autonomy (Impact of
Participation and Autonomy Questionnaire (IPA)). The early ver-
sus delayed palliative care intervention trialled by Dionne-Odom
2015 (Bakitas 2015) showed a 15% difference at one-year survival
(63% early group versus 48% delayed group; P = 0.038). There
was no statistically significant difference in overall median survival
between the groups. The use of chemotherapy in the last 14 days
of life was not statistically different between the groups. About
54% of people in the early group and 47% of people in the delayed
group died at home.
Outcomes related to the health economic effects
None of the included studies reported outcomes related to health
economic effects (e.g. caregiver or patient (or both) employment
status; productivity loss at work; caregiver healthcare utilisation
for acute or chronic (or both) conditions).
D I S C U S S I O N
The aim of this review was to assess the effectiveness of supportive
interventions at improving neuro-oncology caregiver well-being.
The review included eight published studies.
Summary of main results
Overall, evidence was sparse. There was some evidence for positive
effects of caregiver support on psychological distress, mastery, and
QoL (low- to very low-certainty evidence). No studies reported
significant effects on caregiver burden or quality of patient-care-
giver relationship (low- to very low-certainty evidence). None of
the studies assessed caregiver physical functioning. For secondary
outcomes (patient emotional or physical well-being; health eco-
nomic effects), we found very little to no evidence for the effec-
tiveness of caregiver support interventions.
Overall completeness and applicability of
evidence
None of the studies measured all of the primary outcomes in this
review, and even fewer provided data on our secondary outcomes.
Of note, none of the studies assessed caregiver physical functioning
or health economics outcomes. The scarcity of data available was a
major hindrance in assessing the effectiveness of caregiver support.
This review included trials from the US, Australia, the Nether-
lands, and Iran. The perspectives of non-Western countries was
under-represented, which may be highly relevant as differences
in cultural values including family obligations and social support
networks could influence the family caregiving experience (Knight
2010).
We purposefully kept inclusion criteria broad, allowing any type
of supportive intervention, any control group, tested in any pop-
ulation which included at least 20% adult family caregivers who
took care of a patient (of any age) with a primary or secondary
brain or spinal cord tumour. As a result, there was significant het-
erogeneity in populations and interventions. Populations ranged
from parental caregivers of childhood cancer survivors (three stud-
ies), to caregivers of patients with advanced cancer including brain
metastases (one study), to caregivers of patients with pituitary
disease (one study), to caregivers of adult patients with primary
brain tumours (three studies); indicating a degree of heterogene-
ity in the caregiver-patient relationship, as well as patient disease
and prognosis. None of the studies included caregivers of patients
with spinal cord tumours. Four studies tested dyadic interven-
tions which also involved the patient; four were focused solely
on caregivers. A broad range of interventions was included: face-
to-face support based on the principles of CBT, problem-solv-
ing skills training, psychoeducation or cognitive rehabilitation, or
both; early access to palliative care which included coping skills
training; and web-based programmes with or without guidance
from a psychologist. Exposure to the intervention ranged from a
single session taking 10 to 15 minutes to multiple sessions across
three months, with one programme providing monthly follow-up
telephone calls into the bereavement phase. Although beneficial
for external validity, this heterogeneity precluded pooling of data
and meta-analysis.
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Quality of the evidence
We included seven RCTs and one quasi-RCT, which limited the
overall potential selection bias. Together, these studies included
250 neuro-oncology caregivers (range within studies: 13 to 56).
This highlights the main weakness of the state of the evidence -
trials that are likely underpowered to measure the effectiveness of
caregiver support in neuro-oncology introduce potential type II
errors and make it difficult to draw conclusions on efficacy. Au-
thors described three out of eight studies as ’pilot’ or ’feasibility’
studies, and in two cases it remained unclear whether these led
on to larger-scale studies. The Wakefield 2016 study led on to a
full RCT (Wakefield 2015). Due to the nature of supportive in-
terventions, participant blinding is often not possible or desirable;
however, more efforts could have been made to ensure that the
person carrying out statistical analyses is naive to group allocation
- which was only done in two out of eight studies. Participant
attrition and lack of reported reasons may have introduced further
(attrition) bias. Lack of published protocols led to unclear risk of
reporting bias across all included studies.
Outcome measures assessed were not consistent between studies,
with six out of eight studies measuring psychological distress and
QoL, but only two studies assessed caregiver burden and mastery,
and only one study assessed quality of patient-caregiver relation-
ship. Where possible to assess this, study results seemed consis-
tent with either no evidence of effect found, or a positive effect
on caregiver well-being found. The GRADE certainty of evidence
overall was low to very low, with the main reasons for downgrad-
ing being the small sample of neuro-oncology caregivers; and the
heterogeneity of interventions and populations studied.
Potential biases in the review process
We have searched three databases, handsearched relevant confer-
ence abstracts since 2013, and articles published since 2017 in the
two main journals in the field. We searched for ongoing trials and
contacted known experts in the field. Despite this rigorous review
process, it may still be possible that we did not identify all eligible
trials, in particular when the protocol or results were published
after our updated search date (August 2018). Therefore, regular
updates of this review are needed.
Agreements and disagreements with other
studies or reviews
In general, this Cochrane Review highlighted a scarcity of RCTs
investigating support for family caregivers in neuro-oncology.
This lack of literature mirrors the findings of other systematic
(Langbecker 2015;Madsen 2011; Piil 2016; Russell 2014; Sterckx
2013), and non-systematic (Boele 2017b; Sherwood 2016), re-
views that include neuro-oncology caregiver studies, all conclud-
ing that more research is required on caregivers’ unmet needs and
the effectiveness of specific programmes to support neuro-oncol-
ogy caregivers.
There is some additional literature on non-controlled efforts to
improve neuro-oncology caregivers’ well-being. Programmes in-
clude nurse-led interventions, support groups, caregiver work-
shops, psycho-education, patient navigation or care co-ordination,
use of a telephone hotline or brain tumour website, and a dyadic
yoga programme (Boele 2017b; Langbecker 2015; Milbury 2018;
Sherwood 2016). These generally show encouraging results such
as good uptake percentages and qualitative evidence of increased
family autonomy; however, these still need to be evaluated in a
randomised controlled setting.
There has been similar research of other family caregiver popula-
tions. In caregivers of people with terminal illness, one Cochrane
systematic review concluded that support may help reduce care-
givers’ psychological distress (Candy 2011). Another Cochrane
systematic review on non-pharmacological interventions for care-
givers of people with stroke concluded that too few high-quality
RCTs had been published to determine effectiveness (Legg 2011).
In cancer caregivers, one systematic review reporting on 49 inter-
vention studies (not all RCTs) concluded that 65% of the inter-
ventions led to positive and significant improvements in caregiver
or patient well-being (Applebaum 2013). A state of the science
review supported this and stressed the need for guidelines to ad-
vocate changes in clinical practice (Northouse 2012).
The samples of studies included in our Cochrane Review consisted
of very few caregivers of patients with brain metastases and none
of the studies included caregivers of patients with spinal cord tu-
mours. Two systematic reviews similarly reported that very little
is known about the burden and support needs of patients with
brain metastases and their family caregivers (Magbool 2017; Saria
2017). We are not aware of any systematic reviews which have
included support needs or interventions for caregivers of patients
with spinal cord tumours. In adults, most systematic reviews focus
on family caregivers of patients with a high-grade primary malig-
nant brain tumour (Piil 2016; Russell 2014; Sterckx 2013), which
seems reflected in the samples of the studies included in this re-
view.
This pattern is generally mirrored in the series of guidelines pub-
lished by the EuropeanAssociation forNeuro-Oncology (EANO).
For example, the guidelines on meningiomas (Goldbrunner
2016), ependymal tumours (Ruda 2017), and brain metastases
(Soffietti 2017) did not mention caregiver support, whereas the
guidelines for adults with astrocytic or oligodendrial tumours
(Weller 2017) briefly acknowledged the importance of supporting
family caregivers. The palliative care guidelines refer to caregiver
needs throughout (Pace 2017).
Of note, although it is commonly emphasised that support should
not end after the patient has deceased (Petruzzi 2015; Piil 2019),
only one of the included studies in this Cochrane Review con-
tinued to provide some support after the death of the patient
(Dionne-Odom 2015).
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A U T H O R S ’ C O N C L U S I O N S
Implications for practice
This review does not provide the evidence required to demon-
strate whether support for caregivers of people diagnosed with a
brain or spinal cord tumour is effective. The eight trials included
were of small size, included heterogeneous populations, and in-
vestigated effectiveness of a variety of different supportive inter-
ventions. The overall GRADE certainty of evidence was low to
very low. Importantly, no evidence of effect does not equate to
evidence of no effect. There is increased attention for supporting
caregivers, and indeed, new evidence for research is emerging with
five ongoing studies identified during this review. Should a family
caregiver express the need for support, best practice would suggest
that the relevant member of the treatment team would discuss the
lack of evidence with the caregiver, document their views, and use
their clinical judgement to provide recommendations for support
available in their area.
Implications for research
Adequately powered randomised controlled trials are necessary to
determine the effectiveness of caregiver support in neuro-onco-
logical populations, including spinal cord tumours and secondary
brain tumours. Important research questions remain.
• Is caregiver support effective in improving caregiver
emotional or physical well-being (e.g. psychological distress;
caregiver burden; caregiver mastery; quality of patient-caregiver
relationship; quality of life (QoL); physical functioning)?
• Is caregiver support effective in improving patient
emotional or physical well-being (e.g. psychological distress;
QoL; symptom management; number or severity (or both) of
symptoms; number of emergency department visits or
hospitalisations (or both))?
• Are there health economic effects associated with caregiver
support (e.g. caregiver/patient employment status; productivity
loss at work; caregiver healthcare utilisation)?
To reduce potential risk of bias and improve the certainty of
evidence, future studies should ideally include caregivers from
non-Western countries, taking care of people with any brain or
spinal cord tumour, including secondary tumours. Study proto-
cols should be published in advance and care should be taken
to apply blinding where possible (i.e. ensure the person carrying
out statistical analysis is naive to group assignment). Attrition and
other missing data should be adequately reported and handled.
To increase the likelihood of a possible meta-analysis, reporting
should follow CONSORT guidelines.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Andela 2017
Methods Randomised controlled trial
Participants Inclusion criteria: patients in follow-up for pituitary disease in a stable medical situation
and their partners
Exclusion criteria: aged < 18 or > 75 years, receiving intensive medical treatment, or
have psychiatric illness
Number randomised: 188 patients (174 included in analysis). Number of caregivers
randomised not specified, but 63 were included in the analysis (25 intervention group,
38 control group)
Follow-up: baseline, 8 weeks, 6 months
Setting: 2 university medical centres in The Netherlands
Interventions Intervention group: self-management programme drawing on techniques from CBT
consisting of 8 weekly sessions of 90 minutes, guided by psychologists and medical
social workers. Patients and caregivers participated in separate groups of 5-7 participants.
Sessions were named: 1. information; 2. self-monitoring; 3. health promotion; 4. stress
management; 5. management of anxiety and depression/caregivers’ challenge; 6. social
competence; 7. social support; 8. evaluation
Control group: single (optional) information meeting in week 4 or 5
Outcomes Caregiver outcomes
• Mood (Visual Analogue Scale - Mood)
• Self-efficacy (General Self-Efficacy scale)
• Illness perceptions (Brief Illness Perception Questionnaire)
• Coping strategies (the Utrecht Coping List)
• QoL (SF-36)
• Fatigue (Multidimensional Fatigue Inventory-20)
• Anxiety and depression (Hospital Anxiety and Depression Scale)
Patient outcomes
• Mood (Visual Analogue Scale - Mood)
• Self-efficacy (General Self-Efficacy scale)
• Bother and need for support (Leiden Bother and Needs Questionnaire - Pituitary)
• Illness perceptions (Brief Illness Perception Questionnaire)
• Coping strategies (the Utrecht Coping List)
• Participation and autonomy (Impact on Participation and Autonomy)
• QoL (SF-36, EQ-5D)
• Fatigue (Multidimensional Fatigue Inventory-20)
• Anxiety and depression (Hospital Anxiety and Depression Scale)
• Disease-specific QoL (AcroQol, CushingQol)
Notes 22% neuro-oncology (63 caregivers, 25 randomised to the intervention, and 38 to the
control group. 14 caregivers of patients with brain tumours participated)
Risk of bias
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Andela 2017 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Not described in the report. Patients were randomised
using a computer-generated scheme. Caregivers were as-
signed to the same group. Confirmed via correspondence
Allocation concealment (selection bias) Low risk Not described in the report. Computer random number
generator used (confirmed by authors)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding of participants was not possible due to the na-
ture of the intervention
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not described in the report. Analyses were not performed
blind (confirmed via correspondence)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Attrition not described in the report. Level of missing
data was 35% in caregivers (confirmed via correspon-
dence), analysed with linear mixed models. 48% of care-
givers did not complete all intervention sessions
Selective reporting (reporting bias) Unclear risk No published protocol. All caregiver outcomes in the
manuscript were reported on
Boele 2013
Methods Randomised controlled trial
Participants Inclusion criteria: informal caregivers (i.e. a spouse or significant other providing at
least 21 hours of care a week) of patients with a high-grade (WHO grade III or IV)
glioma; aged > 18 years; providing written informed consent
Exclusion criteria: patient life expectancy < 3 months; caregiver was unable to complete
questionnaires due to insufficient mastery of the Dutch language or severe visual impair-
ments; caregiver was unable to understand or apply the skills taught in the intervention
due to physical or mental condition(s)
Number randomised: 56: intervention group 31; control group 25
Follow-up: 8 months
Setting: 3 tertiary referral centres for neuro-oncology patients in The Netherlands
Interventions Intervention group: 6 × 1-hour face-to-face sessionswith a psychologist, on a fortnightly
basis, based on CBT and psychoeducation principles
First, the patient’s symptoms and the caregiver’s involvementwere reviewed, and based on
a prioritisation of the need for help to assist with patient symptoms, the psychologist and
caregiver drew upon a predefined set of strategies. During the first session, patient and
caregiver history and current functioning was documented. During the second session,
an introduction of the intervention and rationale behind CBT was given. For the next
4 sessions, caregivers could make a selection of topics they wanted to discuss. Options
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Boele 2013 (Continued)
were: 1. contact with the patient; 2. the direct environment (contact with family, friends,
and others); 3. epilepsy; 4. changes in behaviour, character, and cognition; 5. time for
yourself; 6. children (what and how to tell them); 7. practical and emotional care in the
end of life phase
Control group: care as usual
Outcomes Caregiver outcomes
• Caregiver mastery (Caregiver Mastery Scale)
• QoL (SF-36)
Outcomes not reported on (confirmed via correspondence)
• Caregiver burden (Caregiving Demands Scale)
Patient outcomes (by proxy):
• QoL (SF-36) - subjective cognitive functioning (MOS Subjective Cognitive
Functioning Scale)
• Disease-specific symptoms (EORTC BN20)
Notes 100% neuro-oncology (56 participants, intervention group 31; control group 25)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Used concealed randomisation technique - drawing a
ticket from a concealed box (confirmed by authors)
Allocation concealment (selection bias) High risk Tickets were not numbered (confirmed by authors).
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding of participants was not possible due to the na-
ture of the intervention
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Analyses were not performed blind (confirmed by au-
thors).
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk High dropout rates (52% in intervention group; 32%
in control group at 8 months’ follow-up). Analysed with
last observation carried forward method
Selective reporting (reporting bias) Unclear risk There was no published study protocol. All outcomes
in the manuscript were reported on. Caregiver burden
data were collected but deemed unreliable (confirmed by
authors)
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Dionne-Odom 2015
Methods Randomised controlled trial
Participants Inclusion criteria: family caregiver (’a person who knows you well and is involved in
your medical care’) of a patient who: was aged > 18 years; had new diagnosis, recurrence,
or progression of an advanced-stage cancer within about 30-60 days of the date the
patient was informed of the diagnosis by his or her oncology clinician; and had an
oncologist-determined prognosis of 6-24 months; was English speaking; was able to
complete baseline questionnaires
Exclusion criteria: scored < 4 on the Callahan Cognitive Screen; had an untreated axis
1 psychiatric condition or an active substance-use disorder; or had uncorrectable hearing
disorder or unreliable telephone service. No additional exclusion criteria for caregivers
Number randomised: 124 dyads (63 early intervention; 61 delayed intervention)
Follow-up: by telephone, once every 6 weeks until 24 weeks; then every 3 months until
end of study or patient death. Not all were followed up after 24 weeks
Setting: participants were recruited from a cancer centre (and affiliated outreach clinics)
and a medical centre in the US
Interventions Intervention group: 3 structured 1-to-1 telephone sessions (with guidebook; once a
week) between an advanced-practice palliative care nurse coach and a caregiver. Session
1 addressed taking on the caregiver role, defined palliative and supportive care, and in-
troduced problem-solving using the framework of the COPE attitude. Session 2 covered
caregiver self-care and effective partnering in patient symptoms assessment and man-
agement. Session 3 addressed the building of a support team, decision making, decision
support, and advance care planning. Sessions lasted on average 23 minutes, and the same
nurse coaches followed up with participants monthly until end of study or patient death
Control group: no treatment but could take part in the intervention after 3 months
Outcomes Caregiver outcomes
• QoL (Caregiver QoL Scale - Cancer)
• Depression (Center for Epidemiologic Study - Depression Scale)
• Caregiver burden (Montgomery-Borgatta Caregiver Burden Scale)
Outcomes reported elsewhere (Dionne-Odom 2016):
• Complicated grief (Prigerson Inventory of Complicated Grief - Short Form)
Outcomes not reported on (confirmed via correspondence):
• Personality traits (NEO Personality Inventory-3)
Patient outcomes (Bakitas 2015):
• QoL (Functional Assessment of Chronic Illness Therapy - Palliative Care;
Treatment Outcome Index)
• Symptom impact (QoL at End of Life Symptom Impact sub scale)
• Mood (Center for Epidemiologic Studies - Depression Scale)
• 1-year and overall survival
• Resource use and location of death (hospital and intensive care unit days,
emergency department visits, period between last assessment and death, chemotherapy
use in last 14 days, location of death)
Notes Published and unpublished data. 22% neuro-oncology (124 participants, 63 to the
intervention group and 61 to the control group. In total, 27 caregivers of patients with
brain tumour were included (3 primary brain tumour; 24 secondary brain tumour;
confirmed via correspondence)
ENABLE III (Educate, Nurture, Advise, Before Life Ends III) trial
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Dionne-Odom 2015 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Not described in the report. Patients were randomised 1:
1 using a computer-generated scheme. Caregivers were
assigned to the same group. Confirmed via correspon-
dence
Allocation concealment (selection bias) Low risk Not described in the report. Computer-generated ran-
domisation after enrolment, confirmed by authors
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding of participants was not possible due to the na-
ture of the intervention
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Analyses were not performed blind (confirmed via corre-
spondence)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Dropout: about 32% of caregivers did not complete all
follow-up assessments; analyses revealed no significant as-
sociations between attrition andmeasured caregiver char-
acteristics or outcome. Maximum likelihood methods
were used to estimate missing outcome data
Selective reporting (reporting bias) Unclear risk There was no published study protocol. All outcomes
specified in the manuscript were reported on; 1 addi-
tional outcome (complicated grief ) was reported in 2016
publication; personality was assessed but not reported on.
Authors confirmed no other outcomes were collected
Klosky 2007a
Methods Randomised controlled trial
Participants Inclusion criteria: parents with a child aged 2-7 years diagnosed with a primary malig-
nancy; English was primary language; no prior experience with external beam radiother-
apy; who were functioning at the level in which the children could tolerate radiotherapy
intervention
Exclusion criteria: not specified.
Number randomised: 80 (41 intervention group, 39 control group).
Follow-up: until the final day of radiotherapy simulation (not further specified). Com-
municationwith authors revealed that this was, inmost cases, approximately a 90-minute
interval between baseline and post assessment
Setting: radiotherapy outpatient clinic in the US.
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Klosky 2007a (Continued)
Interventions Intervention group:CBT package that included exposure to an interactive-educational
ActiMates Barney, an educational video in the clinic room including filmed modelling,
and passive auditory distraction via Barney-narrated stories delivered during the simu-
lation procedure
Modified control group: similar intervention composed of exposure to non-interactive
children’s control character (similar size, colour, and shape to Barney), an age-appropriate
cartoon video, and storied delivered via cassette tape during treatment
Outcomes Caregiver outcomes
• Anxiety (State-Trait Anxiety Inventory)
• Opinions about efficacy of radiotherapy and aspects of the experimental
conditions (study specific Parent Exit questionnaire)
Patient outcomes
• Sedation (anaesthesia administered)
• Behavioural distress (Observation Scale of Behavioral Distress)
• Physiological arousal (heart rate)
• Anxiety (State-Trait Anxiety Inventory)
Notes Primary child outcomes were published previously (Klosky 2004; Klosky 2007b; Tyc
2002). 67% neuro-oncology (80 participants, 41 intervention, 39 control. In total, 53
caregivers of people with brain tumours were included)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Not described in the report. Computer random number
generator used (confirmed by authors)
Allocation concealment (selection bias) Low risk Not described in the report. Computer random number
generator used (confirmed by authors)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not described in the report. The authors explained that
participants were not fully aware of study goals and
would, therefore, not know whether they were assigned
to the intervention or modified control group. However,
they were not formally blinded
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not described in the report. The authors could not re-
member exactly how data analysis was performed
Incomplete outcome data (attrition bias)
All outcomes
Low risk Not described in the report, authors confirmed that there
was no attrition and all participants completed the out-
come measures
Selective reporting (reporting bias) Unclear risk There was no published study protocol. All outcomes in
themanuscript were reported on; other (patient-focused)
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Klosky 2007a (Continued)
outcomes were published elsewhere
Locke 2008
Methods Quasi-randomised controlled trial
Participants Inclusion criteria: people with newly diagnosed primary brain tumour eligible for ra-
diotherapy and aged > 18 years; have mild-to-moderate cognitive impairment; have a
prognosis of≥ 6 months and ability to attend sessions at the medical centre for 2 weeks.
All patients were required to have a designated caregiver available to attend all sessions
Exclusion criteria: none specified.
Number randomised: 16 (9 intervention group, 7 control group). 3 more were not
randomised but allocated to the intervention group
Follow-up: baseline, 2 weeks, 3 months
Setting: tertiary medical centre in US
Interventions Intervention group: received cognitive rehabilitation and problem solving. Cognitive
rehabilitation: dyadswere taught to use a calendar that had a specific format as an external
aid to compensate for cognitive symptoms. 6 × 50-minute sessions over 2-week period.
Specific goals were developed for each session. Problem solving: teaching dyads a model
of stress and a specific problem-solving technique for its management. 6 × 50-minute
sessions over 2-week period, delivered concurrently with the cognitive rehabilitation
intervention
Control group: standard medical care
Outcomes Caregiver outcomes
• Study feedback (study-specific Post-Study Feedback Questionnaire)
• QoL (Linear Analogue Self-Assessment Scale; Caregiver QoL Index-Cancer)
• Distress (Profile of Mood States)
Patient outcomes:
• Compensation techniques (The Compensation Techniques Questionnaire)
• Study feedback (study-specific Post-Study Feedback Questionnaire)
• QoL and functional capacity (Functional Assessment of Cancer Therapy - Brain;
Mayo-Portland Adaptability Inventory-4; Linear Analogue Self-Assessment Scale)
• Cognitive functioning (Repeatable Battery for the Assessment of
Neuropsychological Status)
• Distress (Profile of Mood States)
• Fatigue (Brief Fatigue Inventory)
Notes 100% neuro-oncology (16 participants, 9 intervention group, 7 control group)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Method of randomisation not described. Last 3
participants enrolled were not randomly allocated
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Locke 2008 (Continued)
Allocation concealment (selection bias) High risk Last 3 participants enrolled were not randomly al-
located.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not described in the report, but blinding was likely
not possible due to nature of the intervention
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described in the report.
Incomplete outcome data (attrition bias)
All outcomes
High risk Dropout rates: 26% at postintervention; increased
to 32% at 3 months’ follow-up. 33% did not com-
plete the intervention. Not clear how missing data
were handled, presumably not included in analysis
Selective reporting (reporting bias) Unclear risk There was no published study protocol. All out-
comes in the manuscript were reported on
Reblin 2018
Methods Randomised controlled trial (pilot)
Participants Inclusion criteria: identified as the person who provided the most care for an adult
diagnosed with primary malignant brain tumour; English speaking and reading; having
an email address; aged >18 years
Exclusion criteria: none specified. Authors clarified there were no specific exclusion
criteria, other than not meeting inclusion criteria
Number randomised: 40; 30 intervention group, 10 control group
Follow-up: baseline, 3 weeks, 6 weeks
Setting: National Cancer Institute-designated comprehensive cancer centre in the US
Interventions Intervention group: eSNAP, a web-based application which takes 10-15 minutes to
help caregivers list people or groups who could help within 6 categories of support: 1.
hands-on; 2. informational; 3. communication; 4. financial; 5. emotional; and 6. self-
care. A network visualisation was provided to caregivers in PDF/print
Control group: care as usual
Outcomes Primary outcome (confirmed by authors)
• Feasibility (recruitment and retention rates)
Secondary outcomes:
• Caregiver burden (Zarit Caregiver Burden Scale)
• Distress (Hospital Anxiety and Depression Scale)
• Use of eSNAP (yes/no question of whether participants had reviewed their
network visualisation;
• Satisfaction (single item from 1 (not at all satisfied) to 5 (very satisfied)
Notes 100% neuro-oncology (40 participants; 30 intervention group, 10 control group
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Reblin 2018 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Method of randomisation not described in the
report. Computer randomnumber generator used
(confirmed by authors)
Allocation concealment (selection bias) Low risk Not described in the report. Computer random
number generator used (confirmed by authors)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not possible due to nature of intervention.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Not described in the report. Analysis were per-
formed blind (confirmed by authors)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 20% attrition at 6 weeks. No information pro-
vided on reasons for dropout or how missing data
were handled in the report. Authors confirmed
that within those who completed assessments, <
10% of data were missing and no data imputation
was done
Selective reporting (reporting bias) Unclear risk No published protocol
Safarabadi-Farahani 2016
Methods Randomised controlled trial
Participants Inclusion criteria: primary caregivers of a child with active cancer were eligible if: they
were residents of Tehran; aged > 18 years; patient started treatment process; child aged <
14 years; had access to a telephone at home; and were willing to participate and provide
written consent
Exclusion criteria: none specified
Number randomised: 65 randomised, 3 withdrew due to patient death; 31 intervention
group, 31 control group
Follow-up: baseline, postintervention, 30 days
Setting: hospital and rehabilitation complex in Tehran, Iran
Interventions Intervention group: the Brief Psychosocial Intervention plus usual support services.
Caregivers were provided with information and support through individual counselling
sessions delivered by a trained social worker in 60-90 minutes. Specified sessions goals
were: 1. engage and motivate caregivers to participate and develop open communication
with social worker; 2. develop optimistic attitude, help maintain hope and focus on
achievable short-term goals; 3. provide information about treatments and medication,
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Safarabadi-Farahani 2016 (Continued)
help caregivers learn to live with uncertainty; 4. help caregivers cope with stress and teach
stress-relieving techniques, coping strategies, and healthy lifestyle behaviours; and 5. ed-
ucate self-care strategies. After each session, caregivers received a homework assignment.
Every session was followed up with a telephone call (30-45 minutes)
Control group: usual services, including counselling and financial support
Outcomes • QoL (Caregiver QoL Index Cancer, Persian version)
Notes 48% neuro-oncology (65 participants randomised, 31 intervention group, 31 control
group. In total, 31 caregivers of patients with brain tumours were included)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Method of randomisation not described in the report.
Authors clarified that a member of the team would al-
ternate group allocation in consecutive participants (i.e.
sequence was not random)
Allocation concealment (selection bias) High risk Not described in the report (’centrally randomised’).
Based on the author’s explanations, we concluded that
allocation concealment was not realistically possible
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not possible due to nature of intervention.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not clear if statistician was blinded. Authors explained
that statistician was not in contact with cases, and would
only see study case numbers
Incomplete outcome data (attrition bias)
All outcomes
Low risk 3 study participants dropped out before the baseline as-
sessment. No further information on attrition or how
missing data were handled in the report. Authors con-
firmed that there was no missing data (all questionnaires
were checked directly following completion) and that no
further attrition took place
Selective reporting (reporting bias) Unclear risk No published protocol.
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Wakefield 2016
Methods Randomised controlled trial
Participants Inclusion criteria: parents of children who had finished cancer treatment were eligible
if they: had a child aged ≤ 15 who had completed cancer treatment with curative intent
in the past 5 years; were able to read English; were able to access the Internet in a private
location
Exclusion criteria: parents could not participate if they: had insufficient English skills;
were experiencing extreme anxiety or depression; endorsed current symptoms of psy-
chosis or substance abuse; had a child who was on active treatment, had relapsed, or was
in palliative care
Number randomised: 56 consented and randomised (before baseline), 9 dropped out
before baseline assessment. 25 intervention group; 22 control group
Follow-up: baseline, 2 weeks, 6 months
Setting: children’s hospital in Australia
Interventions Intervention group: Cascade is a manualised programme consisting of 3 weekly 120-
minute online sessions delivered by a psychologist through WebEx. Driven by the the-
oretical models, Cascade targets intra- and interpersonal psychological processes im-
portant to adaptation in the context of illness (e.g. acceptance of uncertainty; practical
problem solving; mobilising social support resources). CBT strategies were used to target
these core mechanisms of change. Topic areas were derived from a previous study (but
not specified in paper). After each session, parents would get homework assignments to
practice
Control group: waiting list control group, parents could participate in Cascade inter-
vention after 6 months
Outcomes • Feasibility (80% completion rate would indicate feasibility; preference for length
of intervention and questionnaires; clinical impressions and technical difficulties)
• Acceptability (California Psychotherapy Alliance Scale-Group short version and
Youth Satisfaction Questionnaire
• QoL (QoL - Family Caregiver Tool)
• Family functioning (McMaster Family Assessment Device)
Notes 28% neuro-oncology (47 participants; 25 intervention group, 22 control group. In total,
13 caregivers of brain tumour patients were included)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Independent personnel used an electronic randomiser to
allocate participants to Cascade or waiting list
Allocation concealment (selection bias) Low risk Independent personnel used an electronic randomiser to
allocate participants to Cascade or waiting list
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not possible due to nature of intervention.
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Wakefield 2016 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The statistician remained blinded until all analyses were
completed
Incomplete outcome data (attrition bias)
All outcomes
High risk Only participants with all 3 assessments completed were
included in analysis of psychosocial outcomes (17%
dropout at 6months in intervention group; 27%dropout
in waiting list control group). Unclear what reasons were
Selective reporting (reporting bias) Unclear risk There was no published study protocol. All outcomes in
the manuscript were reported on
BPI: Brief Psychological Intervention;CBT: cognitive behavioural therapy;COPE:Creativity,Optimism, Planning, Expert Information;
EORTC BN20: European Organization for Research and Treatment of Cancer Brain Cancer Module; EQ-5D: EuroQol; MOS:
Medical Outcome Study; NEO: Neuroticism-Extraversion-Openness; QoL: quality of life; SF-36: 36-item Short Form; WHO:
World Health Organization.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Cernvall 2015 < 20% of the study sample were neuro-oncology family caregivers (15%)
Epstein 2017 Unknown percentage of neuro-oncology caregivers.
Holm 2016 Unknown percentage of neuro-oncology caregivers.
Hudson 2015 < 20% of the study sample were neuro-oncology family caregivers (1%)
Kissane 2016 < 20% of the study sample were neuro-oncology family caregivers (no exact percentage)
Lawsin 2017 Unknown percentage of neuro-oncology caregivers.
Mooney 2015 < 20% of the study sample were neuro-oncology family caregivers (9%)
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Characteristics of ongoing studies [ordered by study ID]
Halkett 2015
Trial name or title Care-IS trial
Methods Multicentre prospective phase III randomised controlled trial
Participants Adult primary carers of a patient with high-grade glioma who 1. is currently undergoing active treatment
and is within 2 months of diagnosis; and 2. is currently attending the outpatient departments of 1 of the
participating sites
The caregiver should furthermore 1. aged >18 years; 2. understand and speak English; 3. have no mental,
cognitive, or functional disability; 4. be willing and able to comply with study requirements; 5. have no
familial, sociological, or geographical condition that might hamper compliance; 6. have no severe intercurrent
medical or psychotic disease that would hinder the ability to participation in the study
Interventions The Care-IS intervention is guided by a nurse and will consist of: 1. a telephone needs assessment; 2. access
to a tailored resource file for the caregiver based on the needs that had been identified; 3. an educational and
supportive home visit from the nurse; 4. monthly telephone check-ups
Outcomes Primary outcomes
• Caregiver preparedness (Preparedness for Caregiving Scale)
• Caregiver distress (Distress Thermometer)
Secondary outcomes
• Anxiety and depression (Hospital Anxiety and Depression Scale)
• QoL (Caregiver QoL Index - Cancer)
• Caregiver competence (Carer Competence Scale)
• Supportive care needs (Partner and Caregivers Supportive Care Needs Scale/Brain Tumour Specific
Supportive Carer Needs for Carers Survey)
• Health economic cost-consequences (checklist of services used)
Starting date 2015
Contact information G.Halkett@curtin.edu.au
Notes
Langbecker 2016
Trial name or title Online psychoeducational intervention for family caregivers of high-grade primary brain tumour patients
Methods Under development. Expected to be tested in a randomised controlled setting following pilot work (com-
mencing 2019)
Phase I: qualitative evaluation of acceptability of the intervention and make modifications
Phase II: single-arm pre-post study to evaluate usability, feasibility, and acceptability
Participants Family caregivers of people with high-grade glioma
Interventions Online psychoeducational intervention based on social cognitive theory
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Langbecker 2016 (Continued)
Outcomes Not yet specified.
Starting date 2019
Contact information d.langbecker@uq.edu.au
Notes Confirmed as accurate 24 January 2019
NCT03454295
Trial name or title Improving palliative care of caregivers of patients with glioblastoma
Methods Randomised controlled trial
Participants Inclusion criteria
Phase I: focus group with GBM caregivers
1. English-speaking, due to the focus groups being managed in English and the use of certain validated
questionnaires only being available in English; 2. aged > 18 years; 3. caregiver to patient with GBM who died
≥ 1 year ago
Phase II: randomised intervention of GBM caregivers
1. English-speaking; 2. current caregiver to a patient with GBM; 3. aged > 18 years; 4. score > 4 on the
Distress Thermometer and indication that this distress is related in some way to the caregiving role per self-
report
Exclusion criteria
1. In the judgement of the consenting professional, clinician or principal investigator, or as per medical record,
severe psychopathology or cognitive impairment likely to interfere with the participation or completion of
the protocol or ability to provide meaningful information; 2. another family member or caregiver to the same
patient is currently enrolled in the study
Interventions Intervention: MCP-C. MCP-C is based on the principles of Viktor Frankl’s Logotherapy. It is designed to
help caregivers of patients with advanced cancer sustain or enhance a sense of meaning, peace, and purpose in
their lives. MCP-C is structured as a 7-session (1-hour weekly or biweekly sessions) individual intervention
that utilises a mixture of didactics, discussion, and experiential exercises that focus around particular themes
related to meaning and cancer caregiving
Control: enhanced usual care. The ’enhancement’ to usual care in this study involves the inclusion of screen-
ing and targeted referral components. Research study assistants conducting the screening and providing feed-
back and referrals will be trained in the National Comprehensive Cancer Network guidelines for distress
management and will discuss the screening results and associated recommendations with the study principal
investigator
Outcomes Aim 1: determine the feasibility, acceptability, and preliminary effects of MCP-C delivered to caregivers of
patients with GBM
Aim 2: to customise the content and format of the MCP-C to address the unique existential and psychosocial
needs of caregivers of patients with GBM
Starting date 12 February 2018
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NCT03454295 (Continued)
Contact information ApplebaA@mskcc.org
Notes Confirmed as accurate 21 January 2019. Phase I is completed, phase II has thus far recruited 10 caregivers
Ownsworth 2015b
Trial name or title Making sense of brain tumor program
Methods Randomised wait-list controlled trial
Participants Aged ≥ 18 years; diagnosed with a primary brain tumour; living within a 1-hour drive of Brisbane; adequate
communication skills; able to provide informed consent. Approximately 60% of the 27 participants in the
intervention group and 23 participants in the wait-list control group had a family member involved in their
programme
Interventions 10 × 1-hour weekly sessions for people with brain tumours, guided by a therapist. Their family members
were encouraged to be involved as well. During the first 2 sessions, participants described their diagnosis,
treatment, and functional changes and set 3-5 goals to focus on.Treatmentmodules includedpsychoeducation,
neuropsychological feedback, cognitive rehabilitation, psychotherapy, and couple and family support. The
last session is used to reflect on the progress and making plans for maintaining and ongoing gains
Outcomes Patient outcomes
• QoL (McGill QoL Questionnaire; Functional Assessment of Cancer Therapy - Brain)
• Depression, anxiety, stress (Montgomery-Åsberg Depression Rating Scale; Depression Anxiety Stress
Scales-21)
Caregiver outcomes
• Unknown. Will be reported in a separate manuscript.
Starting date July 2010
Contact information ownsworth@griffith.edu.au
Notes Confirmed as accurate 29 January 2019. Authors have indicated it is unlikely that caregiver outcomes will be
published separately
Roberge 2016
Trial name or title SmartCare: innovations in caregiving interventions
Methods Randomised controlled trial
Participants Family caregivers (i.e. the primary, non-professional, non-paid caregiver as identified by the patient) of patients
(aged > 21 years; newly diagnosed with a primary malignant brain tumour) could participate if they 1. were
aged > 21 years; 2. had telephone access; 3. could read and speak English; 4. were not currently the primary
caregiver for anyone else other than children aged < 21 years; 5. obtained a score > 6 on the shortened CES-
D; 6. were currently not receiving any type of formal counselling for depressive symptoms
43Interventions to help support caregivers of people with a brain or spinal cord tumour (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Roberge 2016 (Continued)
Interventions The online SmartCare programme takes 8 weeks to complete. Every 2 weeks, participants complete a needs
screening to identify issues that cause distress and are asked to select 1 or 2 issues to work on. Participants
explore the issue in more detail and are encouraged to review past attempts to deal with the issue and any
challenges faced. They are asked to set small, realistic goals related to the issue. Subsequently, the nurse
interventionist provides telephone support to individualise strategies and teach them how to best use the
programme to meet their needs. After 1 week of implementing the plan, the caregiver and nurse review if the
chosen strategies worked adequately and if needed, revise the plan
Outcomes Primary outcomes
• Depressive symptoms (shortened CES-D)
Secondary outcomes
• Unmet needs (Caregiver Needs Screen Questionnaire)
• Caregiver mastery (Caregiver Mastery Scale)
• Optimism (Life Orientation Test)
• Spirituality (Functional Assessment of Chronic Illness Therapy - Spiritual Well-Being scale)
• Oversight demand (Caregiver Vigilance Scale)
• Social support (Interpersonal Support Evaluation List)
• Occupational functioning (Work Limitations Questionnaire)
• Positive aspects of caregiving (Positive Aspects of Caregiving scale)
Starting date 1 March 2014
Contact information prs11@pitt.edu
Notes Confirmed as accurate 28 January 2019.
CES-D: Center for Epidemiological Studies Depression Scale; GBM: glioblastoma multiforme; MCP-C: Meaning-Centered Psy-
chotherapy for Cancer Caregivers; QoL: quality of life.
A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor: [Central Nervous System Neoplasms] explode all trees
#2 ((brain or cereb* or spinal cord or CNS or central nervous system) near/5 (cancer* or carcinoma* or tumor* or tumour* or malignan*
or neoplas* or lymphoma* or hemangioma*))
#3 MeSH descriptor: [Glioma] explode all trees
#4 (glioma* or astrocytoma* or meningioma* or oligodendroglioma* or glioblastoma* or ependymoma* or medulloblastoma* or
craniopharyngioma* or pineal or pituitary or PNET* or DNET* or schwannoma*)
#5 #1 or #2 or #3 or #4
#6 MeSH descriptor: [Caregivers] this term only
#7 MeSH descriptor: [Family] explode all trees
#8 (caregiver* or care giver* or carer*)
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#9 ((family or families or spouse* or partner* or parent* or grandparent* or sibling* or relative* or friend* or husband* or wife or wives
or close person* or significant other* or child or children) and (car*))
#10 #6 or #7 or #8 or #9
#11 #5 and #10
Appendix 2. MEDLINE search strategy
1 exp Central Nervous System Neoplasms/
2 ((brain or cereb* or spinal cord or CNS or central nervous system) adj5 (cancer* or carcinoma* or tumor* or tumour* or malignan*
or neoplas* or lymphoma* or hemangioma*)).mp.
3 exp Glioma/
4 (glioma* or astrocytoma* or meningioma* or oligodendroglioma* or glioblastoma* or ependymoma* or medulloblastoma* or cran-
iopharyngioma* or pineal or pituitary or PNET* or DNET* or schwannoma*).mp.
5 1 or 2 or 3 or 4
6 Caregivers/
7 exp Family/
8 (caregiver* or care giver* or carer*).mp.
9 ((family or families or spouse* or partner* or parent* or grandparent* or sibling* or relative* or friend* or husband* or wife or wives
or close person* or significant other* or child or children) and (car*)).mp.
10 6 or 7 or 8 or 9
11 5 and 10
12 randomized controlled trial.pt.
13 controlled clinical trial.pt.
14 randomized.ab.
15 placebo.ab.
16 clinical trials as topic.sh.
17 randomly.ab.
18 trial.ti.
19 12 or 13 or 14 or 15 or 16 or 17 or 18
20 11 and 19
Key:
mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary
concept word, rare disease supplementary concept word, unique identifier
pt=publication type
sh=subject heading
ab=abstract
Appendix 3. Embase search strategy
1. exp central nervous system tumor/
2. ((brain or cereb* or spinal cord or CNS or central nervous system) adj5 (cancer* or carcinoma* or tumor* or tumour* or malignan*
or neoplas* or lymphoma* or hemangioma*)).mp.
3. exp glioma/
4. (glioma* or astrocytoma* or meningioma* or oligodendroglioma* or glioblastoma* or ependymoma* or medulloblastoma* or
craniopharyngioma* or pineal or pituitary or PNET* or DNET* or schwannoma*).mp.
5. 1 or 2 or 3 or 4
6. exp caregiver/
7. exp family/
8. (caregiver* or care giver* or carer*).mp.
9. ((family or families or spouse* or partner* or parent* or grandparent* or sibling* or relative* or friend* or husband* or wife or wives
or close person* or significant other* or child or children) and car*).mp.
10. 6 or 7 or 8 or 9
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11. 5 and 10
12. crossover procedure/
13. double-blind procedure/
14. randomized controlled trial/
15. single-blind procedure/
16. random*.mp.
17. factorial*.mp.
18. (crossover* or cross over* or cross-over*).mp.
19. placebo*.mp.
20. (double* adj blind*).mp.
21. (singl* adj blind*).mp.
22. assign*.mp.
23. allocat*.mp.
24. volunteer*.mp.
25. 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24
26. 11 and 25
Key:
mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary
concept word, rare disease supplementary concept word, unique identifier
pt=publication type
sh=subject heading
ab=abstract
C O N T R I B U T I O N S O F A U T H O R S
FB handsearched journals and conference abstracts.
FB and AGR performed study selection and data extraction independently.
FB and AGR assessed risk of bias.
FB and HB assessed GRADE certainty of evidence.
FB drafted the manuscript.
The other review authors reviewed the manuscript to improve its quality.
D E C L A R A T I O N S O F I N T E R E S T
FB was involved in a randomised controlled trial aimed at supporting informal caregivers of people with high-grade glioma through
psychoeducation and cognitive behavioural therapy.
PS and FB were involved in a trial to support family caregivers of patients diagnosed with a primary brain tumour through a nurse-
guided online programme (not yet published).
HB: none.
AGR: none.
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S O U R C E S O F S U P P O R T
Internal sources
• New Source of support, Other.
External sources
• Yorkshire Cancer Research University Academic Fellowship, UK.
The lead reviewer is supported by a YCR University Academic Fellowship (L389FB).
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
• To carry out study selection, and ensure at least a degree of generalisability, we had to employ a cut-off for the percentage of
neuro-oncology caregivers in the samples. FB and AR discussed this and set this cut-off at more than 20%.
• The protocol was written in the assumption that a meta-analysis might be possible. After performing the search and study
selection it became apparent that this was not possible - hence some references to meta-analysis methods have been removed.
• Because of the narrative synthesis methods employed, we could not enter the extracted data into Review Manager as planned.
Similarly, we could not assess whether confounding factors influenced study results, and the extent to which these were controlled for
in the analysis (e.g. caregiver education, age, sex, income, socioeconomic status, caregiver use of psychotropic medication, nature of
relationship with the patient, patient diagnosis, patient age, and patient sex). Therefore, we removed the following paragraph from
the ’Data extraction and management’ section: “Where possible, we planned to assess the extent to which the following confounding factors
may have influenced the results and the extent to which these were controlled for in the analysis: caregiver education, caregiver age, caregiver
sex, caregiver income or socioeconomic status, caregiver use of psychotropic medication, nature of the relationship with the patient, patient
diagnosis, patient age, patient sex. Extracted data were entered into Review Manager. Again, the two authors mentioned above discussed and
any uncertainties were resolved by a third review author.”
• There was a change in the author list: C Browne is no longer involved in this review.
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